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PROLOGUE 
 
A pool of literature has emerged recently, describing the 
Microphthalmia/transcription factor E (MiT/TFE)TFEB as a potent inducer of the 
lysosomal and autophagic machineries through the activation of the CLEAR 
network (Sardiello et al, 2009; Settembre et al, 2011; Ballabio, 2016). TFEB 
regulation and activity has been widely investigated, and several papers have 
been published describing how this factor can be regulated by cellular metabolic 
status(Settembre et al, 2013), and how it can lead to the induction of lysosomal 
and autophagy pathways, mediating responses important for cell homeostasis, 
growth, and differentiation (Levy et al, 2006; Sardiello et al, 2009; Settembre et 
al, 2011). Moreover, MITF, TFE3 and TFEC, the other closely-related members 
of the MiT/TFE subfamily (MiT/TFE) (Steingrímsson et al, 2004), have been 
shown to regulate a similar subset of target genes, many of which function in 
autophagy and lysosome (and lysosome-related organelle) biology (Martina et al, 
2014).  
The MiT/TFE transcription factors have also been linked to cancer development. 
Indeed, the Microphthalmia-associated transcription factor (MITF) has been 
described as a key transcription factor in melanoma progression (Garraway et al, 
2005), while TFEB and TFE3 have been implicated in the development of a 
group of novel-identified Renal Cell Carcinomas that are known as TFE-
translocation Renal Cell Carcinomas (TFE-tRCCs) (Kauffman et al, 2014). Fusion 
genes arise from chromosomal translocations involving the TFE3 and TFEB 
genes with different partners. In TFEB-tRCC patients, TFEB protein levels are 
amplified and TFEB is mainly found in the nucleus(Kuiper et al, 2003), while the 
TFE3 fusion gene product was found to be more stable and transcriptionally 
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active than it’s wild-type counterpart (Weterman et al, 2000). It has been almost 
two decades since the initial identification of these chromosomal rearrangements, 
however, the mechanisms responsible for kidney tumour development after 
TFE3/TFEB gene overexpression remains largely uncharacterized (Kauffman et 
al, 2014). Due to this, effective targeted therapies have yet to be identified, hence 
the immediate need to model these diseases in experimental animal systems 
(Kauffman et al, 2014). 
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ABSTRACT 
 
TFE-fusion renal cell carcinomas (TFE-fusion RCCs) are caused by chromosomal 
translocations that lead to the overexpression of the TFE3 and TFEB genes 
(Kauffman et al, 2014). The mechanisms causing kidney tumour development 
starting from TFE3/TFEB gene overexpression, remain largely uncharacterized 
and effective targeted therapies are yet to be identified, hence the need to model 
these diseases in an experimental animal system (Kauffman et al, 2014). Here we 
show that kidney-specific TFEB overexpression, in both constitutive and inducible 
conditional transgenic mouse lines, resulted in a phenotype characterized by renal 
clear cells, multi-layered basement membranes, severe cystic pathology, and 
ultimately papillary carcinomas with hepatic metastases. These features closely 
recapitulate the phenotype observed in both TFEB- and TFE3-mediated human 
kidney tumors. Analysis of kidney samples from these mice revealed both 
transcriptional induction of genes belonging to the WNT pathway and enhanced 
WNT βcatenin signalling. The use of specific WNT signalling inhibitors normalized 
the proliferation rate of primary kidney cells derived from transgenic mice and 
significantly rescued the disease phenotype in the mouse model. These data shed 
new light on the mechanisms underlying TFE-fusion RCCs and suggest a possible 
therapeutic strategy based on the inhibition of the WNT pathway.  
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INTRODUCTION 
 
 
CHAPTER 1. MiT/TFE family of bHLH-LZ transcription 
factors 
 
MITF, TFEB, TFE3 and TFEC are closely related basic helix–loop–helix leucine 
zipper (bHLH-LZ) transcription factors that belong to the MiT/TFE subfamily 
(MiT/TFE) (Hemesath et al, 1994). Many genes important for cell proliferation 
and development belong to the mammals bHLH-LZ factors, such as Myc/Max 
and MyoD (Hemesath et al, 1994).  Most of these family members are able to 
bind the hexamer core CACGTG or (E-box), while the MiT/TFE factors showed 
an higher specificity of binding for M-box, or non-canonical E-box (TCATGTG, 
CATGTGA or TCATGTGA) sites (Hemesath et al, 1994; Aksan & Goding, 1998). 
All the members of the MiT/TFE family share an high homology that include three 
regions: the basic motif that recognizes a specific DNA sequence, the helix-loop-
helix (HLH), and the leucine-zipper (LZ) domain, which are essential for protein-
protein interactions (Steingrímsson et al, 2004). HLH-LZ domains are able to 
homo/hetero-dimerize among themselves, and through these interactions are 
able to bind specific sequences of DNA (Hemesath et al, 1994). Structural 
studies have revealed that these factors share a three-residue shift, defined as 
“kink”, in their Zip domain that allows specific hetero-dimerization among 
themselves, while preventing binding with other bHLH-Zip factors (Pogenberg et 
al, 2012). Specific deletions of the leucine zipper domain are indeed able to 
abolish the DNA-binding ability of these proteins (Hemesath et al, 1994). 
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However, the functional relevance of this hetero/homo-dimerization is still not 
known. TFEB, MITF, and TFE3 can promote transcription through an activation 
domain that is highly conserved among the family members (Beckmann et al, 
1990). This domain, however, is not present in the TFEC gene, which is the most 
divergent family member and seems to act as an inhibitory factor, unlike the other 
three members that activate transcription (Zhao et al, 1993). 
 
 
1.1 MiT/TFE factors: protein function 
 
A recent but large body of evidence underscores the important roles played by 
these transcription factors in many cellular and developmental processes. MITF 
(Mi) protein is mainly expressed in melanocytes, which are the pigment-
producing cells, but it has also been found to have crucial functions in 
osteoclasts, mast-cells, and in the retinal pigmented epithelium (Steingrímsson et 
al, 2004). In melanocytes, it is able to provide a melanocyte-specific signal that 
activates the pigmentation program and is needed for melanocyte survival. It is 
indeed considered a master regulator for melanocyte development (Hemesath et 
al, 1994). MITF is able to induce the expression of specific melanocyte-related 
genes, such as Tyrosinase and TRP-1, through the recognition of an M-box 
element in which the 5’-T (flanking the canonical CATGTG sequence) is highly 
recognized by the MITF gene (Aksan & Goding, 1998). Mice lacking MITF are 
albino, due to the absence of pigmented cells, and have a characteristic 
microphthalmia phenotype (undeveloped eyes) due to the RPE (Retinal 
Pigmented Epithelium) transdifferentiation of the ectopic neural retina (Bumsted 
& Barnstable, 2000). Moreover, in humans, mutations of the MITF gene have 
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been associated with the Waardenburg syndrome Type 2, an inherited syndrome 
associated with hearing loss and pigmentary disturbances (Tassabehji et al, 
1994). TFEC protein expression is restricted to cells of myeloid origin; indeed 
proximal promoter analyses revealed macrophagic-specific features that caused 
TFEC to be classified as a macrophage-specific gene (Rehli et al, 1999).  In 
contrast, TFEB and TFE3 genes are broadly expressed (Kuiper et al, 2004). The 
TFE3 gene was initially identified as a protein that binds the mE3 motif within the 
immunoglobulin heavy chain enhancer (Beckmann et al, 1990), and is implicated, 
together with TFEB, in humoral immunity (Huan et al, 2006) and placental 
vascularization (Steingrimsson et al, 1998), and together with MITF in 
osteoclastogenesis (Hershey & Fisher, 2004). Also, the TFEB gene is considered 
to be a master-regulator of the auto-lysosomal pathway (Ballabio, 2016; Sardiello 
et al, 2009). 
 
 
1.2 The Lysosomes 
 
Lysosomes are cytoplasmic organelles specialized in the degradation and 
recycling of cellular waste. The lysosomal compartment can receive material from 
the extracellular space mainly through endocytosis and phagocytosis, while 
intracellular material is largely delivered by the autophagy pathway (Luzio et al, 
2007). A number of cellular functions depend on a normal lysosomal function: 
cellular constituent turnover, cholesterol homeostasis, antigen presentation, 
plasma membrane remodelling, and bone remodelling (Saftig & Klumperman, 
2009). Lysosomal function can be subdivided into three main activities: 
degradation, secretion, and signalling.  
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1.2.1 Lysosome function: degradation 
Lysosomal degradation occurs through the endocytosis of extracellular material 
and delivery of intracellular material via the autophagy machinery. Endocytosis is 
a term that encompasses many degradative pathways, which include 
phagocytosis, macropinocytosis, clathrin- and caveolin-mediated endocytosis, 
and clathrin- and caveolin-independent pathways. Fission of plasma-membrane 
(PM) invaginations (a dynamin-driven process), results in endocytic vesicles, 
which then undergo several maturation steps to become late endosomes (LEs). 
In LEs, endocytic cargos are sorted into intraluminal vesicles (Xu & Ren, 2015). 
Mature LEs, also known as Multivesicular Bodies (MVB), fuse with lysosomes to 
become endo-lysosomes (ELs). This event is also required for the transport of 
lysosomal hydrolases from the trans-Golgi network (TGN) to lysosomes (Xu & 
Ren, 2015). During endosome-to-lysosome maturation, there is a progressive 
reduction of the luminal pH due to the activation of ATPases that pump protons 
into the lysosome, and of lysosomal membrane channels, such as the cation 
transporter MCOLN1 that mediates Ca2+ release from the lysosomal lumen 
(Mindell, 2012). Alternatively, intracellular material can reach lysosomes through 
the autophagy pathway, a bulk-degradative process used by cells to 
breakdown/recycle cytoplasmic material, including damaged organelles (i.e. 
mitochondria via mitophagy). Autophagy can be further classified into different 
subtypes: microautophagy, chaperon-mediated autophagy (CMA), and 
macroautophagy (which will be called autophagy from hereon). In 
microautophagy, cytosolic proteins are directly engulfed by the lysosomal or 
endosomal membranes (Sahu et al, 2011). In the CMA, proteins are transported 
into the lysosomes through chaperones and receptors, and they need to be 
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unfolded and translocated through the LAMP2A protein (Kaushik & Cuervo, 
2012). Autophagy requires the biogenesis of double membrane vesicles known 
as autophagosomes, which sequester cytoplasmic material. Autophagosomes 
can subsequently fuse directly to lysosomes, or indirectly through LEs, becoming 
autolysosomes (ALs), which then fuse with lysosomes to generate autophago-
lysosomes (Settembre et al, 2013b).  
 
1.2.2 Lysosome function: secretion 
The mechanism associated with lysosome secretion is known as “lysosomal 
exocytosis”, where lysosomes migrate toward the periphery of the cell, fuse with 
the plasma-membrane in a calcium-dependent manner, and subsequently 
release their content into the extracellular matrix (Verhage & Toonen, 2007). 
Lysosomal exocytosis proceeds in two steps; first, upon stimulation, kinesin-
associated lysosomes move from the perinuclear region to the cell periphery 
along microtubules. Second, a pool of pre-docked lysosomes can fuse with the 
plasma membrane in response to calcium-elevation (Jaiswal et al, 2002).  
Initially, this mechanism was considered to be associated only with specialized 
cells containing a subset of lysosome-related organelles (LROs) (Stinchcombe & 
Griffiths, 1999), such as bone resorption in osteoclasts, T lymphocytes 
degranulation, and pigmentation in melanocytic cells (Settembre et al, 2013b). 
However, it has since been shown in all cell types (Rodríguez et al, 1997). 
Lysosomal exocytosis is not only required to admit the release of lysosomal 
material into the extra-cellular space, but it is also really important in the process 
of plasma membrane repair, providing a source of membranes needed during 
injuries (Settembre et al, 2013b).  
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1.2.3 Lysosome function: signalling 
Lysosomes are no longer thought just as organelles involved in degradation and 
cellular clearance, importantly, their activity has now been demonstrated to affect 
a myriad of cellular functions, including lipid homeostasis, plasma membrane 
repair, energy metabolism, bone remodelling, and pathogen defence. Indeed, 
lysosomal activity needs to adapt to external cues and to be finely regulated by 
the metabolic status of the cell (Settembre et al, 2012). The mTORC1 
(mechanistic Target of Rapamicin 1) kinase complex, is a master controller of cell 
and organism growth, and recently it was shown to perform this function on the 
lysosomal membrane (Sancak et al, 2010). The amount of amino acids inside 
lysosomes influences the activation status of mTORC1, thus allowing it’s docking 
on the lysosomal membrane in nutrient replete conditions. Briefly, the v-ATPase 
complex promotes the activation of Rag GTPases, thus recruiting mTORC1 to 
the lysosomal membrane and inducing it’s activation through the small GTPase 
Rheb (Sancak et al, 2010, 2008). During nutrient removal, mTORC1 is released 
from the surface of lysosomes, and this, in turn, allows the activation of a 
lysoNaATP channel that becomes constitutively open and controls lysosomal 
membrane potential, pH, and amino acid homeostasis (Cang et al, 2013). Thus, 
complex protein machinery, involving mTORC1 and other proteins, relies on 
regulation that occurs on the surface of lysosomes and is known as LYNUS 
(Lysosome nutrient sensing). It senses the metabolic status of the cells by 
sensing lysosomal amino acid content, and, subsequently, transmit this 
information to the cytoplasm and the nucleus (Settembre et al, 2013b). 
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1.3 Transcription factor EB (TFEB): a master regulator of the 
autophagic-lysosomal network 
 
Initially, lysosomal activity was considered as a constitutive process, but the 
continuous discovery of new cellular functions that are dependent on these 
organelles, led to the idea that it could be finely regulated. Indeed, Ballabio and 
colleagues recently discovered that lysosomal genes have a coordinated 
expression. Microarray analyses showed that genes encoding for lysosomal 
proteins are co-expressed in different cell types and conditions (Sardiello et al, 
2009). Moreover, a palindromic sequence of 10 base-pairs (GTCACGTGAC) 
localized mainly within 200 base-pairs from the transcription start site (TSS) was 
identified in the promoter region of these genes (Sardiello et al, 2009) and was 
therefore aptly named  Coordinated Lysosomal Expression and Regulation 
(CLEAR) element, which contained the consensus E box (CANNTG) that is 
typically recognized by bHLH-LZ transcription factors (Sardiello et al, 2009).   
TFEB directly binds to the CLEAR element located in the promoter of lysosomal 
genes, including v-ATPase, lysosomal hydrolases, and lysosomal 
transmembrane proteins, thus inducing their expression (Sardiello et al, 2009; 
Palmieri et al, 2011). Consequently, TFEB overexpression was associated with 
higher levels of lysosomal enzymes, thus enhancing lysosomes catabolic 
capacity (Sardiello et al, 2009). This was the first evidence showing that 
lysosomal function was globally regulated, and that TFEB function is 
indispensable for proper cellular metabolic homeostasis. Subsequent work 
revealed that TFEB can also exert its transcriptional control on genes associated 
with autophagy and lysosomal exocytosis (Palmieri et al, 2011). Specifically, it 
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was shown that TFEB can induce autophagy by prompting autophagosome 
formation and autophagosome-lysosome fusion (Settembre et al, 2011). 
Accordingly, TFEB overexpression increased degradation of bulk autophagy 
substrates, such as long-lived proteins (Settembre et al, 2011). TFEB can also 
regulate lysosomal exocytosis (Medina et al, 2011), a process involving the 
trafficking of lysosomes toward the PM, and their subsequent fusion with it, thus 
releasing their content in the extracellular space. Therefore, TFEB coordinates a 
complex transcriptional program that regulates the main degradative cellular 
pathways and thus promoting cellular clearance. Several pathological conditions 
characterized by lysosomal dysfunction can be ameliorated by TFEB 
overexpression in mouse models of human diseases. These include LSDs but 
also α1-anti-trypsin deficiency and other more common diseases such as 
Parkinson’s, Alzheimer’s, and Huntington’s (Ballabio, 2016; Settembre et al, 
2013b). 
 
 
1.4 TFEB regulation 
 
The concept that lysosomes can act as sensing platforms for signals regulation 
resulted in the idea that these organelles are not only required for degradation 
and cellular clearance but are also required as sensors for a variety of cell 
function and homeostasis. The recent discoveries identifying TFEB as the master 
regulator of the “lysosomal gene network” supports this concept. TFEB regulation 
is dependent on post-transcriptional modifications, spatial localization, and 
protein-protein interactions. Under basal conditions, TFEB is mainly localized in 
the cytoplasm of the cell. Specific stimuli, such as starvation, can induce a rapid 
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TFEB translocation in the nucleus (Sardiello et al, 2009; Settembre et al, 2011), 
where it can exert its transcriptional function. Important for TFEB nuclear 
translocation is it’s phosphorylation status; indeed phosphorylated TFEB is 
mainly cytoplasmic, while the dephosphorylated form accumulates in the nucleus. 
Two specific serine residues are essential for TFEB subcellular localization, 
Ser142 (Settembre et al, 2011) and Ser211 (Martina et al, 2012; Roczniak-
Ferguson et al, 2012), and at least three kinases can phosphorylate TFEB:  
ERK2, mTORC1 (Settembre et al, 2012), and PKCb (Ferron et al, 2013).  
Phosphorylation of Ser142 by ERK2 and of both Ser142 and Ser211 by 
mTORC1 are crucial for TFEB localization, and indeed mutants of these residues 
result in nuclear TFEB localization (Settembre et al, 2011; Roczniak-Ferguson et 
al, 2012; Ferron et al, 2013; Martina et al, 2012). During feeding conditions, 
TFEB is phosphorylated and is found in the cytoplasm and on lysosomes due to 
interactions with 14-3-3 protein (Roczniak-Ferguson et al, 2012) and mTOR and 
LYNUS machinery, respectively (Settembre et al, 2012; Martina & Puertollano, 
2013). Interestingly, active Rag GTPases also bind TFEB, mediating its 
recruitment to the lysosomal membrane, promoting its phosphorylation by 
mTORC1 (Martina & Puertollano, 2013). During starvation, lysosomes sense the 
metabolic status through their v-ATPase pumps, thus releasing the mTORC 
complex from their surface as previously described (Sancak et al, 2010). 
Consequently, TFEB is no longer phosphorylated and translocates to the 
nucleus. Moreover, nutrient depletion also coincides with lysosomal calcium 
release from the calcium channel mucolipin 1 (MCOLN1), which in turn activates 
the calcineurin phosphatase that dephosphorylates TFEB, promoting nuclear 
translocation (Medina et al, 2015).  This signalling network is of significant 
relevance for the coordination and activation of a transcriptional program that 
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allows cells to sense and adapt to nutrient status. Furthermore, it has been 
demonstrated that TFEB regulates the transcription of many genes important for 
its own regulation, such as v-ATPase subunits, MCOLN1 and numerous 
lysosomal enzymes.  This reinforces the idea that lysosomal adaptation to 
external stimuli is regulated by multiple feedback loops. In accordance with this, 
TFEB nuclear translocation can also induce its own transcription, in a positive 
autoregulatory loop that is dependent on the presence of CLEAR elements 
located in its promoter. Thus, starvation can induce TFEB activity using dual 
mechanisms (Fig. 1) (Roczniak-Ferguson et al, 2012; Settembre et al, 2013a, 
2012).  
 
modified from Settembre et al.,  Nat Rev Mol Cell Biol 2013 
Figure 1. TFEB regulation model.  
TFEB is induced by starvation and mediates the starvation response. In the presence of nutrients, 
TFEB interacts with the LYNUS machinery and is phosphorylated by mTORC1, on the lysosomal 
surface. This phosphorylation inactivates TFEB keeping it in the cytoplasm. During starvation, 
mTORC1 is no longer on the lysosome, and consequently TFEB is not phosphorylated and it 
translocates into the nucleus, where it induces its own transcription and the transcription of its 
target genes, like the genes involved in the lysosomal-autophagy pathway.   
 
Importantly, similar regulation mechanisms were also observed for the other MiT 
transcription factors(Martina et al, 2014; Martina & Puertollano, 2013). Finally, 
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recent data showed a possible role of WNT pathway in the regulation of the TFE-
factors. MITF was shown to be regulated by the GSK kinase, whose activation is 
important for the regulation of the WNT pathway (Ploper et al, 2015). MITF 
protein has three C-terminus phosphorylation sites that are phylogenetically 
conserved and also found in TFEB (S397, S401 and S405) and are efficiently 
phosphorylated by GSK (Ploper et al, 2015). Considering that GSK protein 
kinase activation triggers the proteasomal degradation ofcatenin, a key player 
in WNT pathway, Ploper et al. postulated that these kinase could be important to 
regulate the stability of the MITF protein, and possibly of the other MiT-TFE 
factors (Ploper et al, 2015).  
In conclusion, identification of TFEB, and the study of its transcriptional network, 
underlined new mechanisms through which cells can respond to metabolic 
changes, such as nutrient availability. In the lysosomal context, TFEB resulted to 
participate in a lysosome-to-nucleus signalling, converting lysosomal status in a 
transcriptional response. However, how different stimuli can activate different MiT 
members, and which cell responses they modulate, still need to be investigated.  
Regarding this, in the past few years, mutations involving TFEB, TFE3 and MITF 
genes had been identified in different cancerous condition. Amplifications and 
activating mutations of the MITF gene had been observed in melanoma, and in 
some forms of hereditary Renal Cell Carcinoma (Ugurel et al, 2007; Bertolotto et 
al, 2011), whereas chromosomal translocations leading to the overactivation of 
TFEB and TFE3 genes had been identified in sporadic Renal Cell Carcinomas 
herein referred as TFE-fusion RCC (Kauffman et al, 2014). These findings 
opened a new field of study, thus conveying the interest for these factors toward 
the cancer field.  
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CHAPTER 2. Renal Cell Carcinomas 
 
Kidney cancer is a complex disease, because of its heterogeneity in terms of 
genetic background, histology, therapies and prognosis. A lot of efforts have 
been spent to unravel the nature of the different forms of cancer that occur in the 
kidney. Kidney cancer results from mutations in a number of different genes, 
which have unique histology profiles, require different therapies resulting in poor 
and promising prognoses, as some kidney lesions are aggressive and others 
quite indolent (Linehan et al, 2010). Renal Cell Carcinomas (RCCs) originate 
from the renal epithelium and include several heterogeneous subgroups defined 
according to their histological phenotype. The most frequent sporadic forms of 
RCCs are Clear Cells (65-70%) , type 1 papillary (10%), type 2 papillary (5%), 
TFE-fusion RCC (1-5%), cromophobe (5%) and oncocytoma (5%) (Amin et al, 
2002; Linehan, 2012). Each of these kidney cancer subtypes has its own 
histology profile, outcome and responds to different therapies. 
 
 
2.1 Renal Cell Carcinoma: genes and syndromes 
 
Studies of the inherited forms of kidney disease, such as von Hippel-Lindau 
(VHL) syndrome and the Birt-Hogg-Dubé (BHD) syndrome, have led to the 
identification of genes important for RCC. To date, mutations in 12 different 
genes (VHL, MET, FH, FLCN, SDHB, SDHC, SDHD, TSC1, TSC2, PTEN, MiTF 
and BAP1) have been associated with an increased susceptibility in the 
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development of RCC (Linehan & Ricketts, 2013). Consistent with this, mutations 
in the VHL gene, that are responsible of the VHL syndrome, are found in the 
majority of cases with sporadic Clear Cell RCCs. Moreover, the Met gene is 
mutated in all patients with hereditary papillary renal carcinoma, and is also found 
mutated in a small population of patients with sporadic, type 1 papillary kidney 
cancer. Mutations of the fumarate hydrolase gene (FH) are responsible for the 
inherited form of type 2 papillary kidney cancer associated with the 
leiomyomatosis renal cell carcinoma (HLRCC), but in this case sporadic type 2 
RCC is a mixture of kidney cancers, and the gene(s) responsible are currently 
under investigation. Folliculin (FLCN) is mutated in 96% of patients with inherited 
chromophobe RCC and oncocytoma associated with BHD syndrome. TFEB, 
TFE3, and MITF, are however only mutated in non-hereditary papillary kidney 
cancers, whereas germline gain-of-function mutations of MITF have been 
discovered in patients with melanoma, but rarely with kidney cancer (Linehan, 
2012) (see Fig. 2).  
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. 
From Linehan et al., Genome Research 2012 
Figure 2. Description of the main RCC subtypes. 
Classification of the main forms of kidney cancers accordingly with their histology and genetic 
mutations. 
 
 
 
 
2.2 Clear Cell Renal Cell Carcinoma (ccRCC): The VHL gene 
 
Clear Cell Renal Cell Carcinoma (ccRCC) is the most common type of RCC. 
Initially, it was associated with deletions of the short arm of chromosome three 
(Linehan & Zbar, 1987). Subsequently, investigators identified mutations in the 
VHL gene causing the hereditary form of ccRCC, VHL syndrome. Patients with 
VHL syndrome also have a higher risk of developing cancers in a number of 
other organs, including the kidney, where they can develop, in early stages, a 
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multifocal clear cell kidney cancer. It is reported that almost 35-45% of patients 
with the VHL syndrome ultimately die of kidney cancer (Linehan, 2012).  Indeed, 
renal kidney tumours continuously develop, and they are surgically resected 
when a 3cm threshold is reached (Herring et al, 2001). 
To understand if mutations in the VHL gene were also responsible of the non-
hereditary sporadic forms of kidney cancers, an in-depth mutational analysis of 
the VHL gene was performed in patients with kidney cancer. Gene alterations 
were found in nearly 90% of patients with ccRCC (Nickerson et al, 2008), 
whereas they were not observed in patients with other forms of RCC, like 
papillary or cromophobe RCC, thus underscoring the relevance of this gene in 
ccRCCs. The VHL protein binds the HIF-1alpha and HIF-2alpha transcription 
factors, thus enabling their targeting for ubiquitin-dependent proteasomal 
degradation. In normoxia, the VHL complex binds and ubiquitylates the hypoxia-
inducible factors, conversely, under hypoxia, formation of the VHL complex is 
inhibited allowing for HIF factors to accumulate in the nucleus and subsequently 
to transcribe their target genes, like the vascular endothelial growth factor 
(VEGFA), the glucose transporter GLUT1, and the epidermal growth factor 
(EGFR) (Kaelin, 2008). HIF-1aplha is ubiquitously expressed and  primarily 
targets genes involved in glycolysis, whereas HIF-2alpha is the primary regulator 
of erythropoietin and of the stem cell factor OCT4 (Shen & Kaelin, 2013).  
Targeting the vascular endothelial growth factor receptor is still the most effective 
treatment for advanced ccRCC. 
More recently, new genes responsible of sporadic forms of ccRCC are being 
discovered. These genes are involved in the maintenance of chromatin status, 
like the histone modifier SETD2 and the SWI/SNF chromatin remodeller complex 
gene PBRM1(Dalgliesh et al, 2010; Varela et al, 2011). Detailed mechanistic 
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analyses will be required for the better understanding of the role of these genes 
in kidney cancer. 
 
 
2.3 Hereditary forms of kidney cancer 
 
Mutations in the proto-oncogene MET are responsible for hereditary papillary 
renal cell carcinoma (HPRC), and have also been found in patients with 
nonhereditary papillary kidney cancer (Schmidt et al, 1997). MET gene encodes 
for the cell surface receptor for hepatocyte growth factor (HGF) and cancerous 
mutations usually occur in the tyrosine kinase domain of MET, thus enabling the 
use of molecules with dual kinase activity able to target both MET and VEGF 
receptors in patients with HPRC and sporadic papillary RCC (Choueiri et al, 
2013). However, therapeutic treatments for these patients also require the 
surgical removal of tumours larger than 3cm.   
Patients affected by the Birt-Hogg-Dubè (BHD) syndrome are at risk of 
developing bilateral, multifocal kidney cancer as well as pulmonary cysts and 
fibrofolliculomas (Zbar et al, 2002). While patients affected by VHL or HPRT 
develop respectively  ccRCC or papillary RCC, BHD patients can develop 
different histological types of kidney cancer, but more frequently hybrid oncocytic 
tumours and chromophobe renal carcinoma are observed. These patients are 
managed in the same way of patients with VHL and HPRC, tumours are 
surgically resected at 3cm (Pavlovich et al, 2005). Recently, linkage analysis on 
BHD families led to the identification of mutations in the Folliculin (FLCN) gene. 
FLCN works as a tumour suppressor gene, and mutations have been found in a 
high percentage of BHD families (Nickerson et al, 2002). FLCN interacts with two 
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proteins, FNIP1 and FNIP2, and with AMPK, which negatively regulates mTOR. 
FLCN can control a number of processes, and interestingly it can modulate 
amino acid-dependent mTOR activation through Rag GTPases, and TFEB and 
TFE3 activity (Schmidt & Linehan, 2015; Hong et al, 2010; Petit et al, 2013).   
Hereditary leiomyomatosis renal cell carcinoma (HLRCC) patients can develop 
cutaneous and uterine leiomyomas, which are fibroid tumours, and type 2 
papillary kidney cancer (Launonen et al, 2001). Renal cancers are aggressive, 
and even tumours of small mass have high metastatic potential, thus surveillance 
is not recommended and extensive surgical procedures typically are performed 
immediately (Linehan, 2012). The gene responsible for the disease is the 
fumarate hydrolase (FH) gene, a Krebs cycle enzyme. FH-deficient kidney 
cancers have high aerobic glycolysis and are dependent on glucose transport, a 
hallmark of the Warburg effect, which postulates that some cancers require 
glycolysis for ATP production, while they have impaired oxidative phosphorylation 
(Yang et al). For this reason new therapies are now in development for HLRCC 
patients, targeting the tumour vasculature and the glucose transport (Linehan & 
Rathmell, 2012).  
Succinate dehydrogenase renal cell carcinoma is an inherited syndrome 
associated with the development of pheochromocytomas and paragangliomas, 
rare tumours arising from the neural crests, and oncocytic kidney cancer 
(Vanharanta et al, 2004). Renal cancers can be very aggressive, and they should 
be immediately removed as soon as they are identified. Mutations have been 
identified in the SDHB and SDHD genes, which are two of the four genes 
encoding for the mitochondrial succinate dehydrogenase. These cancer also 
behave in accordance with the Warburg effect theory (Vanharanta et al, 2004; 
Linehan, 2012). 
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Inactivating mutations of both alleles of TSC1 or TSC2, which are the two 
members of the tuberosclerosis (TSC) compex, lead to the development of an 
hereditary syndrome associated with the growth of tumours in a number of 
tissues, included kidney. Usually, kidneys are affected by angiomyolipomas 
(AMLs), a kind of benign renal neoplasm composed of smooth muscle, 
vasculature, and fat cells. Rarely, TSC patients can also develop RCC (Linehan, 
2012). TSC1/2 complex, is required for mTOR shut-down, consequently, 
inactivating mutations activates constitutively the  mTOR pathway, increasing 
cellular growth.  
TFEB and TFE3 genes have been linked to chromosomal translocations 
associated with the development of Renal Cell Carcinomas (RCCs). These 
Translocation Renal Cell carcinomas (TRCCs) are rare kidney cancers that were 
added to the 2004 to the World Health Organization (WHO) classification (Argani 
& Ladanyi, 2005) and defined as TFE-fusion RCCs (Kauffman et al, 2014).  This 
group of tumours will be described in detail below. 
 
 
2.4 Molecular pathways altered in kidney cancer 
 
All the identified cancer genes, VHL, MET, FLCN, FH, SD, TSC1, TSC2, TFEB 
and TFE3, participate in the control of different aspects of cellular metabolism, 
including nutrient, oxygen, and energy sensing. The identification of such genes 
has led to the better understanding of the biochemical basis of kidney cancer and 
of the principal signalling pathways altered in these cancers (Fig. 3).  
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From Linehan et al., Genome Research 2012 
Figure 3. Kidney cancer gene pathways. 
Genes associated to kidney cancer development, VHL, MET, FLCN, FH, SDH, TSC1, TSC2, and 
TFE3, affects the capability of the cell to sense oxygen, iron, nutrients and energy. VHL targets 
HIF-1alpha for ubiquitin-mediated degradation. The FLCN/FNIP1/FNIP2 complex can bind 
AMPK, and FLCN is phosphorylated by mTOR. TSC1/2 are phosphorylated by the LKB/AMPK 
cascade and mediate cell’s response to energy. FH and SDH are Krebs cycle enzymes, when 
they are deficiently the cell requires glycolysis for energy production. Moreover, their deficiency 
also dysregulate HIF degradation, and this leads to increase GLUT1 levels which enables 
transport of glucose and ATP production. 
 
 
2.6 Sporadic RCCs-papillary kidney cancer 
 
Papillary RCC has been widely characterized, and now is a well-established 
entity in terms of morphological, immunohistochemical and cytogenetic features. 
Papillary kidney cancer has been sub-classified in two different types, type 1 and 
type 2, in accordance with their histology. Type 1 papillary RCC is characterized 
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by the presence of tightly formed papillae covered by small cuboidal cells, with a 
single line of uniform nuclei and nucleoli. In type 2, papillae are large and less 
organized, and are covered by large eosinophilic cells with irregular nuclei. Type 
1 papillary kidney cancer is much more frequent then type 2, and patients have a 
much better prognosis, while type 2 RCCs tend to metastasize early (Leroy et al, 
2002; Linehan, 2012). 
Little is known about the molecular basis of papillary RCC, indeed mutations in 
the MET gene were commonly found only in a subset of patients with sporadic 
type 1 papillary kidney cancer. However, recent TCGA data collected on a large 
population of patients, affected by type 1 and 2 papillary RCC, revealed that 
alterations of MET status (defined as mutation, splice variant, or gene fusion) or 
increased chromosome 7 copy numbers (where the MET gene is located) were 
identified in 81% of type 1 papillary renal-cell carcinomas (Linehan et al, 2015). 
Type 2 RCC showed high heterogeneity. 25% of patients screened showed 
mutations or alterations in the CDKN2A gene, leading to gene silencing. Other 
type 2 tumours were associated with mutations in the chromatin-modifying genes 
SETD2, BAP1, and PBRM1, which are frequently mutated in ccRCCs in 
combination with loss of chromosome 3p. A CpG island methylator phenotype 
(CIMP) was observed in a sub-group of type 2 RCCs with poor survival and 
mutations in the FH gene (Linehan et al, 2015). Finally, chromosomal 
translocations involving TFEB and TFE3 genes were also identified in patients 
with type 2 papillary RCC, suggesting that these tumours are underappreciated in 
type 2 patients as they are the only recurrent translocation in kidney cancers 
(Linehan et al, 2015; Malouf et al, 2014). 
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CHAPTER 3. TFE-fusion RCCs 
All the MiT-TFE family members have been associated with cancer development. 
MITF has been associated with Melanoma and with hereditary forms of 
hereditary RCC. TFEB and TFE3 genes are found fused to different gene 
partners in sporadic RCCs (see Table 1) (Kauffman et al, 2014). 
 
 
From Linehan et al., Nat. Rev. Uorol. 2014 
Table 1. Clinical mutations of the Mit family transcription factors. 
 
TFEB and TFE3-translocation RCCs are a histologically variable group of 
sporadic tumours representing almost 2% of all the RCCs (Komai et al, 2009) 
and approximately 12% of type 2 papillary renal cell carcinoma (Cancer Genome 
Atlas Research Network et al, 2016). Initially, TFE-fusion RCCs were 
predominantly observed in paediatric patients, comprising, according to Argani et 
al. (Argani & Ladanyi, 2005), almost one third of all the paediatric cases of RCCs. 
Currently TFE-fusion RCCs are also considered relatively common in adult 
patients younger than 45 years old (Komai et al, 2009). Recent large-scale next-
generation genetic analyses evidenced the frequent occurrence of TFEB and 
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TFE3 translocations in RCCs (Linehan et al, 2015; Malouf et al, 2014). Moreover, 
recent evidences also showed an association of previous chemotherapy 
exposure with development of translocation RCC. Approximately 10-15% of 
tRCCs have been observed after a previous exposure to cytotoxic drugs (Argani 
et al, 2006). TFE3-tRCCs are usually aggressive and often metastasize, while 
TFEB-tRCCs usually have a better prognosis. However,  the molecular basis of 
these cancers are currently poorly understood, and this has hampered the 
identification of a promising pharmacological treatments (Argani & Ladanyi, 
2005).  
 
3.1 TFEB-translocation RCC: molecular basis 
 
In most cases, TFEB-tRCCs are the consequence of a well-characterized 
chromosomal translocation involving the TFEB gene, on chromosome 6p21.2, and 
the non-coding Alpha gene (or MALAT1) located on chromosome 11q13, 
generating an Alpha-TFEB fusion (t(6;11)(p21.2;q13) (Davis et al, 2003; Kuiper, 
2003). TFEB contains two noncoding and eight coding exons. The ATG starting 
codon is located in exon 3, and the stop codon is situated in exon 10, as depicted 
in Figure 4. The translocation breakpoint in TFEB generally is located in exon 3, 
just upstream of the ATG start codon, thus resulting in the retention of the entire 
TFEB coding sequence. At the end of the translocation event, the Alpha promoter 
drives the expression of the fusion gene. Importantly, the Alpha gene does not 
contribute to the open reading frame, thus causing only a promoter substitution 
event (Davis et al, 2003; Kuiper, 2003). The consequence of the Alpha-TFEB 
fusion gene is a significant overexpression of the full-length TFEB protein, which 
accumulates inside the nucleus. Indeed, overexpression and nuclear accumulation 
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of TFEB are considered to be a diagnostic marker of the disease (Kuiper, 2003). 
All cases involving TFEB breakpoints were observed within a 289bp cluster region 
(BCR) upstream exon 3, thus retaining the entire TFEB coding sequence (Davis et 
al, 2003; Argani et al, 2005; Inamura et al, 2012). However, only recently a new 
breakpoint was identified in three patients within exon 4, but the protein size 
appears to be the same as the wild-type protein (Inamura et al, 2012) (Fig. 4).  
 
 
From Linehan et al., Nat. Rev. Urol. 2014 
Figure 4. MALAT1-TFEB gene fusions. 
The figure is a schematic representing exons and functional domains of the TFEB gene. The 
common breakpoint cluster region (BCR) is represented in light grey, while the darker region is the 
recently published BCR extension. All the MALAT1-TFEB gene fusions contain an upstream 
MALAT1 region (red) and most of the TFEB gene (blue-grey). Thin regions of the gene represent 
noncoding regions, whereas the thick region represents the translating reading frame. AD, strong 
transcription activating domain; BCR, breakpoint cluster region; bHLH, basic helix-loop-helix 
domain; LZ, leucine zipper domain. 
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In rare cases of TFEB-fusion RCCs, TFEB can translocate with the KHDBRS2 
(inv(6) (p21;q11)) (Malouf et al, 2014) and the CLTC (t(6;17)(p21;q23)) genes 
(Durinck et al, 2015). KHDBRS2 is a gene involved in RNA splicing, and the TFEB 
breakpoint was located within the 5’ end of the gene, thus retaining most of the 
TFEB coding sequence (Malouf et al, 2014). The TFEB-CLTC fusion gene was 
identified in a non-ccRCC sample previously reported as unclassified. In this case, 
the fusion protein contained the bHLH domain of TFEB, suggesting that the 
retained TFEB gene is still functional (Durinck et al, 2015). Thus, even if new 
TFEB-fusion RCCs have been recently identified, it looks like TFEB is still the 
driving force of the neoplastic transformation.   
 
 
3.2 TFE3-translocation RCC: molecular basis 
 
 
TFE3 chromosomal translocations appear to be more complicated. TFE3 was 
found to be involved in translocations with five known gene partners (i.e. PRCC, 
ASPSCR1, SFQP, NONO, CLTC) leading to the generation of fusion proteins. The 
first translocation was the PRCC-TFE3 t(X;1)(p11.2;q21.2), identified in 1986 in a 
paediatric patient (de Jong et al, 1986) and characterized in 1995 due to the 
derivation of three cell lines, UOK120, UOK124 and UOK146 (Sidhar et al, 1996). 
Subsequently, this translocation was also identified in young adults (Tonk et al, 
1995). The following derivation of two additional cell lines, UOK145 and UOK109, 
led to the identification of novel gene fusion products, the SFQP-TFE3 (previously 
known as PSF) and the NONO-TFE3 gene fusions (Clark et al, 1997). Finally, 
Argani et al. identified other two gene fusions, ASPSCR1-TFE3 (Argani et al, 
2001) and CLTC-TFE3 (Argani et al, 2003).  The identification of multiple TFE3-
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gene partners strongly suggests that RCC is caused by TFE3, rather than by its 
fusion partners (Kauffman et al, 2014). The exact breakpoint varies in TFE3, and 
usually occurs in different introns of both TFE3 and its gene partner. Fusion of 
chimeric mRNA happens at the exon-exon junctions, retaining the reading frame 
of the fusion transcript, while containing the N-terminal portion of the gene partner 
and a variable range of exons located in the C-terminal part of TFE3 gene.  TFE3 
exon 1 is commonly absent, while the universally retained region of the chimeric 
protein includes exon 6 to 10, encoding for a 208 amino acid C-terminal peptide 
containing the bHLH/LZ dimerization and DNA binding domain. In total, five 
translocation gene partners have been identified for TFE3-tRCCs. Of these, only 
PRCC-TFE3, SFQP-TFE3 and ASPSCR1-TFE3 have been identified as common 
translocations, while NONO-TFE3 and CLTC-TFE3 were observed only in single 
patients. Moreover, ASPSCR1-TFE3 was also found in patients with alveolar soft 
part sarcoma (APS) and SFPQ-TFE3 was found in a subset of patients with a rare 
tumour known as perivascular epithelioid cell neoplasms (PEComas). All the 
identified gene fusions are listed in Table 2. 
 
INTRODUCTION 
 
43 
 
  
From Linehan et al., Nat. Rev. Urol,. 2014 
Table 2. TFE3 gene fusions in RCCs. 
 
Recent TCGA analyses showed that among all the screened TFE-tRCC tumours, 
only one had mutations in the VHL gene, and none of them had mutations in other 
genes commonly observed in cc-RCCs (Network et al, 2013). Together, these 
data suggest that the first step, and driving force, of the disease pathological 
cascade is the overexpression of active TFEB and TFE3 proteins, which is likely 
associated with an increase of their function as transcription factors. 
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3.3 Mechanisms of TFE-fusion oncogenesis 
 
Fusion genes can cause tumorigenesis mainly through three mechanisms. The 
“lost activity model” happens when a translocation event causes the loss of 
function of a tumour suppressor gene. The “novel activity model”, presumes that 
the fusion event generates new protein functions leading to a transformation 
event. Finally, the “dysregulated activity model” is the commonly accepted model 
for TFEB and TFE3-tRCCs. In this case, the TFE-fusion event increments a pre-
existing oncogenic activity of the wild-type protein through changes in the 
promoter of the TFEB or TFE3 genes. Indeed, all TFE3 gene partner promoters 
are constitutively active causing TFE3 protein to be expressed at higher levels and 
the fusion protein results in a more stable and transcriptionally active gene product 
than the wild-type protein (Weterman et al, 2000; Clark et al, 1997; Argani et al, 
2003). In TFEB-tRCC, there is a promoter substitution leading to the up-regulation 
of the wild-type TFEB, thus the “dysregulated activity model” is aptly applied. This 
model implies that TFEB and TFE3 genes have intrinsic oncogenic activities, and 
this has been demonstrated for some members of the MiT-TFE family. For 
example, specific NONO-TFE3 knockdown can inhibit the soft-agar colonization 
phenotype associated with UOK-109 cells, and this, in turn, can be re-established 
by the induction of the MITF protein (Davis et al, 2006). Moreover, this theory has 
also been confirmed by clinical observations, considering that MiTF is amplified in 
20% of metastatic melanoma and activating mutations of this gene have been 
identified in hereditary RCC as well as melanoma (Cronin et al, 2009; Bertolotto et 
al, 2011). 
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3.4 Candidate TFE-driven signalling pathways  
 
Ones established that TFEB and TFE3 genes overexpression/overactivation are 
the drivers of carcinogenesis in TFE-tRCCs, research interest conveyed toward 
the identification of molecular pathways that could be altered by these genes and 
responsible of cancer insurgency. To date, there has been limited data available 
on the biological pathways involved in these TFE-fusion tumours, and this has 
hampered the identification of target therapies (Kauffman et al, 2014). Argani et al. 
(Argani et al, 2010) reported activation of the mTOR pathway in TFE-tRCC 
patients compared to ccRCCs, as shown by increased phosphorylation levels of 
the downstream mTOR target S6. Unfortunately, selective mTORC1 inhibition 
performed on patients with TFE-tRCCs did not improve the disease phenotype 
(Malouf et al, 2010). Up-regulation of the MET-tyrosine kinase receptor, which in 
turn activates HGF-signalling, was detected by Tsuda et al. in TFE-tRCC patients 
by in vitro assays (Tsuda et al, 2007), however subsequent analyses on TFE3-
renal samples failed to identify activated MET protein (Kauffman et al, 2014) and 
treatment of TFE3-tRCC patient cells with a MET-inhibitor required an extremely 
high drug concentration to observe an inhibition of cell growth, consistent with the 
response observed in cells with no MET activation (Guo et al, 2010). Moreover, a 
clinical trial using tivantinib, a MET inhibitor, demonstrated poor response on TFE-
RCC patients (Wagner et al, 2012).  Some patients with metastatic TFE3-tRCC 
have been treated with inhibitors of ErbB receptors and of the mTOR pathway. 
Unfortunately, most of these patients relapsed after an initial period of remission 
(Parikh et al, 2009; Wu et al, 2008). Other hypotheses have been proposed 
regarding the involvement of possible molecular pathways in carcinogenesis. 
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TFE3 can interact with SMAD proteins, resulting in TGF-beta signalling (Hua et al, 
2000), which can have a key relevance in carcinogenesis mediating initiate 
immune evasion, growth factor production and metastatic dissemination. 
Moreover, TFE3 can also bind to the ETS transcription factor, that belongs to a 
gene family associated with fusion events in prostate cancer and sarcomas (Tian 
et al, 1999).  TFEB and TFE3 can also regulate transcription of E-cadherin, 
important in cell-cell interaction, and CD40L, for primary T lymphocytes activation 
(Huan et al, 2006). Another mechanism putatively involved in carcinogenesis is 
activation of the lysosomal-autophagy pathway. Considering the well described 
role of TFEB as master regulator of these pathways (Sardiello et al, 2009; 
Settembre et al, 2011; Ballabio, 2016) and the recent evidence indicating that 
activation of autophagy driven by MiT/TFE genes plays an important role in 
pancreatic cancer (Perera et al, 2015), a general idea is that carcinogenesis can 
be mediated by the autophagy machinery. Autophagy is an essential mechanism 
for nutrient recycling during cellular starvation, but until now there are no direct 
evidences of its involvement of in TFE-fusion RCC pathogenesis. Further, recent 
data showed that MITF protein overexpression can positively regulate WNT 
pathway in melanoma cell lines, and that this, in turn, is able to determine a 
nuclear accumulation of MITF in a positive feed-back loop (Ploper et al, 2015), 
thus introducing the idea that WNT pathway can mediate a role in the TFE-driven 
carcinogenesis by increasing the nuclear amount of MITF protein and by 
enhancing the WNT signalling.  
In conclusion, nearly two decades have passed from the identification of TFE-
tRCCs and we currently still do not have effective therapies for these cancers. 
Significant efforts have been made for the histological and molecular description of 
these cancers, and recent TCGA data have given new insights in the disease 
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characterization. Despite this though, the altered molecular events responsible for 
the disease pathogenesis and progression have to be identified, thus preventing 
the finding of specific therapies.  
 
 
CHAPTHER 4. WNT signalling  
 
 
WNT proteins are a group of 19 highly conserved secreted glycoproteins (Papkoff 
et al, 1987)  that direct cell proliferation, migration, survival, polarity and cell fate. 
WNT pathway is particularly active during embryonic development and tissue 
homeostasis, and is involved in stem-cell control and renewal (Anastas & Moon, 
2013). Considering this, perturbations of this pathway have been associated with 
different human diseases, including cancer (Anastas & Moon, 2013).  Currently, 
there are three different pathways activated by WNT ligands: the canonical WNT-
catenin cascade, WNT non-canonical planar cell polarity pathway, and the 
WNT/Ca2+ pathway. Among these three, the canonical WNT/catenin pathway is 
the best characterized.  
 
 
4.1 Complexity of WNT glycoprotein secretion 
 
WNT glycoproteins are a family of highly hydrophobic and conserved molecules, 
and they are characterized by the presence of a N-terminal signal peptide required 
for their secretion. Lipid modified WNT glycoproteins are widely observed in 
Metazoans, ranging from the sea anemone Nematostella, to humans, thus 
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implying that they are involved in a variety of functions (Clevers, 2006). Murine 
Wnt1, also known as Int1, was the first discovered WNT gene. It was identified in 
1982 as proto-oncogene activated by integration of a mouse mammary tumour 
virus (Nusse & Varmus, 1982). Later, the identification of the wingless (Wg) 
polarity gene as orthologous to Wnt1 in D. Melanogaster, led to the generation of 
the name WNT, as a fusion of Wg and INT (Rijsewijk et al, 1987). WNT proteins 
can be distributed in a graded manner among tissues, thus inducing WNT 
signalling at different levels. Control of WNT proteins secretion is important and 
needs to be finely regulated (Hausmann et al, 2007). Three factors have been 
recently identified as regulators of WNT secretion: lipoprotein particles (Panáková 
et al, 2005), the retromer complex (Coudreuse et al, 2006), and the multi-pass 
transmembrane protein Wntless (WLS) (Bänziger et al, 2006). 
. 
4.1.1 WNT glycosylation 
At the primary sequence level, WNT proteins share a pattern of 23 cysteine 
residues, that are required for protein palmitoilation (Willert et al, 2003), the N-
terminal signal sequence, and several glycosylation sites. WNT glycosylation is 
still not completely understood. It may be required for targeting WNT proteins to 
the exocytic route and it may also affect the extracellular distribution of WNT 
proteins. Glycosylated-deficient WNT3a and WNT5a proteins are defective in 
secretion whereas, glycosylated-deficient WNT1 protein can be secreted and can 
promote WNT signalling in cultured cells (Tang et al, 2012). These results indicate 
that the involvement of glycosylation in WNT secretion is not a common 
mechanism among different WNT proteins. Moreover, lipidation-defective Wg 
protein can be glycosylated, suggesting that glycosylation and lipidation are two 
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independent processes (Tang et al, 2012). Further investigations are still required 
to completely understand the functions of glycosylation in WNT proteins. 
 
4.1.2 WNT lipidation 
WNT lipidation is also essential for WNT proteins localization and function. Two 
lipid modifications have been identified on mature WNTs, initially identified on 
WNT3A. Murine WNT3A was the first isolated and characterized WNT protein 
(Willert et al, 2003). This protein is N-glycosylated to allow its secretion, and these 
lipid modifications are required for its hydrophobicity and poor solubility 
(Hausmann et al, 2007). The first identified lipidation site was cysteine 77, which is 
conserved in all WNT proteins and mutation of this residue has no effect on 
protein secretion, but diminished WNT3a ability to activate catenin signalling 
(Willert et al, 2003). Another lipidation site was subsequently identified, serine 209, 
for protein palmitoylation. Lesions in serine 209 result in the accumulation of 
WNT3A in the endoplasmic reticulum, which fails to be secreted (Takada et al, 
2006). Thus, cysteine 77 palmitoylation is required for normal function of secreted 
WNT proteins, while palmitoylation of serine 209 is required for correct protein 
trafficking. The importance of WNT lipidation is also evident from the discovery of 
Porcupine (PORC), an acyltransferase that has been proposed to be the enzyme 
required for the addition of acyl groups to both Cys77 and Ser209 (Willert et al, 
2003). Porcupine is a multi-pass transmembrane protein active only in WNT-
producing cells and belongs to the O-acyltransferase superfamily (Hofmann, 2000; 
Kadowaki et al, 1996). PORC is localized to the ER and WNT secretion is 
significantly abrogated in PORC null cells. Blocking Ser209 palmitoylation 
resembles the phenotype of Porcupine loss-of-function, suggesting that Porcupine 
is responsible for this modification (Takada et al, 2006). Finally, the recent solving 
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of WNT8 crystal structure has revealed that WNT proteins can bind to their 
Frizzled receptor due to the presence of two domains projecting into the receptor 
pocket, and one of these domains contains a palmitoleic acid lipid necessary for 
this interaction. Thus, lipid signalling resulted to play an important role in WNT 
pathway, as it is required for a correct trafficking, secretion and activity of WNT 
proteins. 
 
4.1.3 Wntless proteins and the retromer complex 
Wntless (Wls) protein is a seven-pass transmembrane protein important for WNT 
secretion. Wls localizes at the Golgi network, endosomes, and plasma membrane, 
and binds WNT proteins (Fig. 5). Wls is thought to act as a sorting receptor, 
shuttling WNT proteins from the Golgi and delivering them to the plasma 
membrane. Moreover, studies in C. elegans demonstrated the importance of the 
retromer trafficking complex in WNT signalling. This complex involves the 
retrograde transport of endocytosed transmembrane proteins back to the Trans-
Golgi network. In yeast, the retromer complex is important for the recycling of the 
hydrolase transporter Vps10, while in mammals it is required for mannose-6-
phospate receptor trafficking. Recent evidences revealed that the retromer 
complex also retrieves endosomal Wls protein, avoiding its lysosomal degradation 
and mediating its trafficking back to the trans-Golgi network (Belenkaya et al, 
2008) (Fig. 5).  
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From Clevers et al., Cell 2012 
Figure 5. The WNT secretion machinery. 
WNT proteins are lipidated in the ER by the PORC enzyme. Subsequently, trafficking and secretion 
is dependent from the Wls transmembrane proteins. The retromer complex is required for recycling 
the Wls endosomal vesicles.  
 
Indeed, the loss of retromer function leads to degradation of Wls in lysosomes and 
reduction in WNT secretion. Vacuolar acidification is required for the release of 
WNT proteins from the Wls molecule and drugs inhibiting the V-ATPase proton 
pump can prevent the release of WNT protein, thus leading to an accumulation of 
WNTs-Wls complexes both in cells and plasma-membrane (Willert & Nusse, 
2012). 
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4.1.4 WNT proteins are not classical morphogens 
WNT proteins are normally considered morphogens, meaning that these 
molecules are able to exert their function across long distances. A well-known 
example of WNT morphogen action occurs at the wing imaginal disk of Drosophila. 
Wg protein is produced by a thin layer of cells, which subsequently dispersed from 
this tissue, mediating varying molecular responses over long distances. Wg 
proteins can mediate this kind of action in two ways: by their association with 
lipoprotein particles (Panáková et al, 2005) or by their interaction with specific 
binding partners, like the Swim protein (Mulligan et al, 2012). However, with the 
exception of wing development in Drosophila, Wg rarely mediates long-range 
signals, rather they usually mediate contact-dependent signalling. In other 
animals, WNT signalling appears to occur predominantly in cells that are close to 
each other, thus these molecules are not considered classical morphogens, but 
they can signal at short distances (Clevers & Nusse, 2012).  
 
 
4.2  The catenin cytoplasmic destruction complex 
 
In the absence of WNT morphogen stimulation, WNT pathway is not active 
andcatenin protein is degraded by the proteasome. catenin is a key player in 
the canonical WNT pathway and its levels and localization need to be finely 
regulated. catenin levels are strictly controlled by the cytoplasmic destruction 
complex, which is a complex made up of multiple proteins, like Axin and APC. Axin 
is a tumour suppressor gene that acts as the scaffold for the destruction complex, 
it can interact with catenin, the tumour suppressor proteins APC, and WTX, with 
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the two constitutively active serine-threonine kinases CK1 and GSK3Axin is 
phosphorylated by the kinases CK1 and GSK3, while it is dephosphorylated by 
the PP1 and PP2C phosphatases. There are two Axin genes in the human 
genome and they encode for Axin1 and Axin2. Axin is a member of the catenin 
degradation complex, yet Axin 2 expression levels are upregulated by the 
WNT/catenin pathway. Moreover, there are three Nuclear Localization Signals 
(NLS) in Axin that may serve as a shuttle for catenin between the cytoplasm and 
nucleus (Cong & Varmus, 2004). APC is the largest structural protein of the 
destruction complex. It interacts with both catenin and Axin due to the presence 
of three Axin-binding motifs interposed between 15-20 amino acids repeats that 
bind catenin. The APC-catenin binding domains are thought to be required for 
the exposure of catenin phosphorylation residues to the destruction complex. 
APC can be phosphorylated by the CK1 kinase and this phosphorylation 
outcompetes Axin to form a complex with catenin. Additionally, it has been 
proposed that coordination of Axin, APC, and catenin phosphorylation is 
necessary for catenin processing in the degradation complex (Verheyen & 
Gottardi, 2010).  APC function is still not completely understood, although it is 
clear that it is essential for the destruction complex activity. APC has also been 
demonstrated to function as a nuclear shuttling protein, indeed APC has two NLSs 
required to shuttle APC into the nucleus (Zhang et al, 2000). Further, nuclear APC 
was shown to negatively regulate the transcriptional activity of catenin (Voronkov 
& Krauss, 2013).  Finally, WTX is another member of the destruction complex and 
it is mutated in some forms of paediatric kidney cancer (Rivera et al, 2007), 
however, the exact function of WTX is not well defined.When the WNT pathway is 
inactive, WNT receptors are not engaged and CK1/GSK3 kinases phosphorylate 
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Axin-bound catenin at N-terminal Ser/Thr residues (Verheyen & Gottardi, 2010). 
Initially, CK1 phosphorylates catenin at Ser45, enabling a subsequent 
phosphorylation by GSK on Ser33, Ser37, and Ser41. These phosphorylation 
events increase APC affinity for catenin, thus allowing the transfer of catenin 
from Axin to APC and the loading of a new catenin molecule on Axin . Finally, 
APC exposes the phosphorylated motif to the Fbox/WD repeat protein TrCP 
(Voronkov & Krauss, 2013) that is part of an E3 ubiquitin ligase complex. catenin 
is then ubiquitinated and ultimately degraded by the proteasome (Aberle et al, 
1997).  
 
 
4.3 WNT receptors 
 
Activation of WNT signalling requires the binding of the secreted WNT proteins to 
WNT receptors. WNT proteins can bind a heterodimeric receptor complex located 
on the cell surface, composed of Frizzled (FZD) and LRP5/6. FZD proteins are 
seven transmembrane receptors with a large N-terminal cysteine-rich domain 
(CRD) important for WNT binding (Janda et al, 2012). FZDs interact with a single 
pass transmembrane protein of the LRP family, known as LRP5/6 in vertebrates 
(Pinson et al, 2000). Currently, the most popular model proposes that WNT binds 
to FZD, which triggers the hetero-oligomerization of the FZD-LRP5/6 complex, 
also known as the WNT signalosome, thus activating WNT/catenin signalling 
(Tolwinski et al, 2003). WNT signalosome oligomerization is induced on its 
cytoplasmic domain by Dishevelled (DVL). DVL can interact with the cytoplasmic 
tail of FZD (Clevers & Nusse, 2012) and can oligomerize through its DIX domains, 
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which are motifs that share homology with the Axin domain (Voronkov & Krauss, 
2013; Fiedler et al, 2011). The DVL-mediated FZD-LRP5/6 oligomerization is then 
needed for Axin recruitment to the WNT signalosome, inducing Axin 
polymerization on the cytoplasmic side of the signalosome (Voronkov & Krauss, 
2013). Axin and the kinases CK1 and GSK3 are recruited to LRP5/6 (Del Valle-
Pérez et al, 2011).  First, CK1–mediated phosphorylation acts as a primer that 
allows for GSK3-mediated phosphorylation of LRP5/6. CK1 and GSK3 can 
recognize and phosphorylate PP(S/T)PX(S/T) repeats in the cytoplasmic tail of 
LRP5/6, initiating the crucial event of catenin stabilization, as these kinases can 
switch from phosphorylating catenin to phosphorylate LRP5/6. The degradation 
complex subsequently becomes rapidly saturated by phospho-catenin, and the 
newly synthesized protein accumulates in the cytoplasm and translocates into the 
nucleus, thus activating the transcription of its target genes (Li et al, 2012) (Fig. 6).  
 
 
Modified from Clevers et al., Cell 2012 
Figure 6. The WNT signalosome and the degradation machinery. 
In the absence of Wnt, the destruction complex localizes in the cytoplasm where it binds, 
phosphorylates, and ubiquitinates catenin through b-TrCP. Wnt induces the association of the 
intact complex with phosphorylated LRP. After binding to LRP, the destruction complex stills 
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captures and phosphorylates catenin, but ubiquitination by b-TrCP is blocked. Newly synthesized 
catenin accumulates. 
 
The WNT signalosome can also activate WNT pathway indirectly, by inducing Axin 
degradation and GSK3 inhibition (Cselenyi et al, 2008) or by sequestering GSK3 
in multivesicular endosomes that reduce the kinase presence at the cell surface 
(Taelman et al, 2010).  
  
 
4.4 Adherens complex and catenin signalling  
 
catenin can also mediate a transcriptional-independent function, which happens 
at the cell surface. In this context, catenin can bind different cadherins, like E-
cadherin, mediating the generation of adherens junctions (Clevers & Nusse, 
2012). The adherens junction pool is highly stable, and it has multiple functions in 
the cell, like structural adhesion functions, protective roles, and it participates in 
signalling pathways, with a prominent role in WNT/catenin signalling (Brooke et 
al, 2012). Cadherins are a family of single-pass transmembrane proteins and the 
central components of the adherens junctions. Changes in cadherins 
concentration are referred to as “switch”, as for example the increase in N-
cadherins against E-cadherins observed in epithelial to mesenchymal transition 
(EMT). Cadherins switch is important for cell motility, migration, invasiveness and 
metastasis in cancer (Voronkov & Krauss, 2013). As an example of the importance 
of cadherins switch, E-cadherin adhesion complexes are considered to be one of 
the key regulators of cytoplasmic catenin pool, and a reduction of E-cadherin 
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content is sufficient to induce an increase of catenin levels and transcriptional 
activity (Brembeck et al, 2006). E-cadherin is a single-pass transmembrane 
protein that has an N-terminal extracellular domain which is important for cell-cell 
adhesion and consists of five repeats that are stabilized by calcium (Voronkov & 
Krauss, 2013). The intracellular part of the protein contains a juxtamembrane 
domain (JMD) that promotes adhesion complexes to bind catenin, plakoglobin, 
as well as p120 and catenin (Ishiyama et al, 2010). There are different 
mechanisms by which catenin can be modulated at the adherens junctions. For 
example, catenin phosphorylation by PKA appears to promote its stability and, 
subsequently, binding to the Creb binding protein CBP, thus inducing catenin-
mediated signalling (Hino et al, 2005). Moreover, the cellular kinase Src (c-Src) 
can phosphorylate catenin, impairing its binding with E-cadherin, and leading to 
an increase in its cytoplasmic levels (Voronkov & Krauss, 2013). Finally, WNT 
binding to FZD/LRP receptors also induces a CK1-dependent E-cadherin 
phosphorylation that reduces the affinity of βcatenin to E-cadherin, leading to the 
release of βcatenin. Hence, WNT signalling stimulation can also induce a release 
of the membrane-bound form of βcatenin, further increasing its protein levels 
(Voronkov & Krauss, 2013).  
 
4.4.1 Additional transmembrane receptors influencing catenin 
c-Met, the receptor of the hepatocyte growth factor/scatter factor (HGF), has been 
associated with WNT/catenin signalling, and it has been shown that it can 
activate catenin at the site of the adherens junctions (Nelson & Nusse, 2004). 
HGR binding to c-Met stimulates an autophosphorylation of the receptor that in 
turn mediates catenin phosphorylation on Tyr654 and Tyr670, leading to catenin 
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dissociation from E-cadherin (Nelson & Nusse, 2004). HGF can also induce 
catenin release through a matrix metalloproteinase-7 (MMP-7)-dependent E-
cadherin degradation (Pan et al, 2010), or through the induction of the 
transcription factor Snail, that represses E-cadherin expression (Leroy & Mostov, 
2007). HGF/c-Met-mediated stabilization of β-catenin has been associated with 
several types of tumours (Ranganathan et al). 
 
 
4.5 catenin nuclear function 
 
Once released from the destruction complex, cytoplasmic catenin translocates 
into the nucleus where it can exert its main functions. Here catenin interacts with 
a number of transcription factors and predominantly with the zinc-finger 
transcriptional factors of the Tcf/Lef ( T-cell factor/lymphoid enhancer 
factor) family. These factors were originally identified in the immune system, 
however the discovery of the interaction between TCF/LEF and catenin revealed 
a wider role in WNT signalling. All the members of the Tcf/Lef family (Tcf1, Tcf3, 
Tcf4, and Lef1) have an N-terminal catenin binding domain, followed by a 
context-dependent regulatory domain (CRD) able to bind the co-repressor Grucho 
(Gro), a HMG-box DNA-binding domain, and a C-terminal domain with binding 
sites for the co-repressor C-terminal binding protein (CtBP) (Arce et al, 2006). Lef1 
generally works as a transcriptional activator when complexed with catenin. Tcf3 
is instead predominantly considered as a repressor. Tcf1 and Tcf4 are context-
dependent and can work both as repressors or activators of transcription (Arce et 
al, 2006). The consensus TCF cognate motif in vertebrate is AGATCAAAGG (van 
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de Wetering et al, 1997) and it has been used for the generation of a WNT/TCF 
reporter, the pTOPflash plasmid containing concatamers of this motif (Korinek et 
al, 1997). In the absence of catenin, Tcf/Lef members bind DNA and form a 
repressor complex with Grucho, CtBP and HDAC, leading to transcriptional 
repression (Clevers & Nusse, 2012). When catenin translocates into the nucleus, 
it displaces the repressor complex bound to Tcf/Lef factors, facilitating the Tcf/Lef 
binding with co-activators such as CBP/p300, and BCL9/LGS and Pygo, which can 
activate transcription of target genes (Fig. 7) (Clevers & Nusse, 2012).  
 
 
Modified from Clevers et al., Cell 2012 
Figure 7. WNT signalling in the nucleus. 
In the absence of WNT signals, TCF represses its target genes through the binding with 
corepressors such as Groucho. Upon WNT signalling, catenin replaces Groucho from TCF and 
recruits transcriptional coactivators and histone modifiers such as Brg1, CBP, Cdc47, Bcl9, and 
Pygopus to drive target gene expression. 
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There is no consensus on the mechanism by which catenin travels between 
cytoplasm and nucleus, and in many cases WNT stimulation leads to an overall 
increase in catenin protein levels, without a clear nuclear localization. catenin 
nuclear import depends from the Nuclear Localization Signal/importin machinery 
and it can be actively exported back to the cytoplasm either by an export signal or 
as cargo of Axin or APC (Clevers, 2006). A number of WNT target genes have 
been identified  in different biological systems. Until now, the direct “WNT target 
genes”, contain a TCF binding site. To this category of genes belong cMyc, Cyclin 
D1 and Axin2 (Clevers 2006).  
 
 
4.6 WNT antagonists  
 
WNT signalling pathway can be inhibited at different levels. One possibility is to 
inhibit WNT signalling through the use of secreted molecules able to antagonize 
WNT ligands, which include frizzled secreted proteins (sFRPs), WNT inhibitory 
proteins (WIPs), Dickkopf (DKK) and Cerberus. sFRP, WIP and Cerberus inhibit 
WNT by blocking the interaction between WNT ligands and Fzd receptors 
(Bovolenta et al, 2008). DKK1 molecules act by disrupting the Fz-LRP complex 
(Clevers & Nusse, 2012). Moreover, the WNT pathway can be targeted by Axin 
degradation; Axin N-terminal phosphorylation results in increased affinity for 
catenin and thus, catenin degradation. Inhibition of the Axin phosphatases 
PP2A and PP1, via okadaic acid, can induce catenin degradation (Voronkov & 
Krauss, 2013). Other druggable molecules include the Tankyrase proteins, 
Tankyrase 1 (PARP5a) and Tankyrase 2 (PARP5b), which are Poly (ADP-ribose) 
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polymerases (PARPs) that are implicated in WNT signalling. PARPs mediate the 
addition of a multimeric side chain by the use of a NAD+ molecule as a substrate, 
and these proteins appear to interact with the ubiquitin ligase RNF146, which is 
essential for Axin degradation by the destruction complex. Thus, Tankyrase 
inhibitors can inhibit WNT signalling by blocking Axin degradation (Voronkov & 
Krauss, 2013). Porcupine is another protein that could be a target for the 
modulation of WNT signalling, as it is required for proper WNT secretion. IWP are 
a class of potent small molecules targeting Porcupine, and thereby inhibiting WNT 
secretion. (Voronkov & Krauss, 2013). Finally, a group of small molecules were 
found to disrupt the β-catenin/Tcf-4complex: CGP049090, PKF118-310, PKF115-
584 and ZTM000990. Studies revealed that the binding sites for these molecules 
in βcatenin corresponds to a cavity located inside amino-acids Arg469, Lys435, 
Lys508, Glu571 and Arg515 which interacts with Tcf-4 (Voronkov & Krauss, 2013). 
The use of these small molecules, which sterically hindered substrate binding, 
inhibited colon cancer cell lines proliferation in vitro (Wei et al, 2010), disrupted the 
β-catenin/Tcf-4complex in vivo, and was able to eradicate breast cancer in a 
Her2/Neu mouse model of breast cancer (Hallett et al, 2012).  
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CHAPTHER 5. WNT signalling in the kidney 
 
WNT signalling plays important roles during embryonic kidney development. WNT-
mediated signalling regulates kidney development from early stages of renal 
organogenesis, and aberrant WNT signalling can lead to kidney diseases ranging 
from fatal kidney agenesis to milder phenotypes.  
 
 
5.1 Renal organogenesis 
 
Renal organogenesis starts from early metanephros, which  begins with the 
outbranching of the Wolffian duct, the ureteric bud (UB), and the metanephric 
mesenchyme (MM).  The MM is subdivided into cap mesenchyme (CM) that is 
adjacent to the UB, and cortical interstitial stroma that surrounds the CM (Halt & 
Vainio, 2014). After the metanephros establishment, the UB undergoes iterative 
branching, while the CM begins to differentiate into nephrons in the regions 
surrounding the UB. Progenitor cells located in this position, generate pre-tubular 
aggregates that subsequently undergo a Mesenchymal-to-epithelial (MET) 
transition to generate a renal vesicle, which will ultimately differentiate into the 
collecting duct system generated by the UB (Halt & Vainio, 2014). Renal vesicles 
mature into functional nephrons through the evolution of comma-bodies into S-
shaped bodies, elongating along the corticomedullary axis, and forming the region 
that contains the Bowman’s capsule, the proximal convoluted tubule, the loop of 
Henle, the distal convoluted tubule, and the collecting tube. On the vascular side 
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of the kidney, the nephron connects with the glomerulus, which is composed of 
endothelial and mesangial cells (Halt & Vainio, 2014) (Fig. 8). 
 
 
From Sampogna et al., Physiology 2004 
Figure 8. Renal branching morphogenesis and nephron formation. 
Ureteric bud (UB) outgrowth is induced by signals arising from the metanephric mesenchyme (A, 
B). This is followed by iterative branching of the UB and stalk elongation (C, D). At the branch tips, 
the UB induces a mesenchymal-to-epithelial transformation (E, F) via the formation of comma- and 
S-shaped bodies (G, H), ultimately forming various nephron components (I). 
 
In this context, generation and study of several knockout models has helped the 
understanding of the transcriptional program responsible for nephrogenesis. The 
sine oculis-related homeobox 2 (Six2) gene is essential for the developing kidney, 
as it is expressed in the nephron stem cell population needed to maintain the self-
renewal potential, while its expression is rapidly down-regulated in the pre-tubular 
cell aggregates to allow differentiation initiation (Halt & Vainio, 2014).  Upon 
induction, cells of the cap mesenchyme down-regulate Six2 and activate genes 
like Fgf8, Wnt4, Lhx1 and Pax8 to allow pretubular aggregate formation (Halt & 
Vainio, 2014). In these developmental stages, WNT signalling plays important 
roles. It is involved both during the initial induction of the CM and during nephron 
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maturation, and alterations of WNT signalling in this stage can severely affect 
renal organogenesis, resulting in different pathological conditions like polycystic 
kidney disease and Wilms tumour.  
 
 
5.2 WNT signalling in nephrogenesis 
 
In vitro experiments have revealed that contacts between CM and UB is the key 
stimulus for successful kidney development. Indeed, separation of CM from MM 
leads to a regression of both tissues in culture (Kispert et al, 1998). In this context, 
MM development can be rescued from degeneration and differentiate into 
nephrons through the addition of the embryonic spinal cord (eSC). eSC can 
mediate MM development mainly through the production of WNTs. WNT4 was 
identified as the major molecule expressed in the CM and the principal 
nephrogenic inducer (Halt & Vainio, 2014), while WNT9b was also shown to be 
essential to induce CM differentiation (Carroll et al, 2005). WNT9b was identified 
as the primary UB-derived factor able to stimulate exit of CM from a stemness 
state. WNT9b is mainly expressed in the Wolffian duct and in the UB, and its 
expression is retained in collecting ducts until adulthood. In mice, Wnt9b 
expression induced the production of Wnt4, Fgf8, Pax8, and Lhx1, while these 
genes were not expressed in the CM of Wnt9b-deficient kidneys, thus resulting in 
the absence of nephron generation (Halt & Vainio, 2014).  Similar to Wnt9b, Wnt4 
depletion inhibits nephron differentiation, resulting in a vestigial kidney (Stark et al, 
1994). The WNT4 gene acts in the CM downstream of WNT9b, inducing LHX1 
activation in pre-tubular aggregates, and subsequently promoting renal vesicle 
epithelialization and thus MET progression (Halt & Vainio, 2014). Several studies 
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have been performed to address the effects of WNT signalling in nephron 
maturation. In one study, TCF-reporter mouse lines revealed an activation of 
WNT/TCF pathway in embryonic kidney (Barolo, 2006). Moreover, WNT activation 
was observed only in the UB and not in the MM, and addition of catenin 
stabilizing small molecules or GSK3 inhibitors in the separated MM promoted the 
expression of the WNT/βcatenin/TCF feedback genes: Lef1, Tcf1, and Wnt4 
(Kuure et al, 2007). Further, kidney specific βcatenin knock-out mice demonstrated 
a failure to induce CM development due to reduction in the expression of Fgf8, 
Pax8, Wnt4, and Lhx1, whereas ectopic expression of an active βcatenin form led 
to an ectopic CM induction and to a premature depletion of the renal stem cell pool 
(Halt & Vainio, 2014). In summary, βcatenin is sufficient to activate the nephron 
stem cell pool to promote nephron differentiation, via the the β-catenin/TCF/Lef 
pathway mediated up-regulation of Fgf8 and Wnt4. Additionally, WNT4-dependent 
MET induction does not proceed through canonical catenin signalling, indeed, 
forcing an aberrant catenin response in mice resulting in negatively regulation of 
the epithelialization process (Park et al, 2007). In this context, the 
WNT/Calcium/NFAT (nuclear factor of activated T cells) signalling was shown to 
function as a downstream effector of WNT4 in pre-tubular aggregates (Tanigawa 
et al, 2011). During MET initiation, early nephrons expressed the calcineurin-
dependent NFAT factor, while the calcineurin inhibitor increased nephrogenesis. In 
addition, WNT4 also induced calcium influx together with the calcium/calmodulin-
dependent protein kinase II phosphorylation in primary MM cells. This data 
indicated that WNT4 functions in the CM, at least in part through the 
Calcium/NFAT pathway. After MET establishment, nephrons need to growth in an 
oriented manner along their Y-axis. This complex architecture requires an oriented 
INTRODUCTION 
 
66 
 
cell division and coordinated motility, and WNT signalling has been shown to 
control these processes through the coordination of a planar cell polarity (PCP) 
pathway. De-regulation of WNT leads to pathophysiological changes and kidney 
cystic disease (Lancaster & Gleeson, 2010), thus it is reasonable to conclude that 
the WNT/PCP pathway plays an essential role after MET establishment. Given 
that the WNT/βcatenin pathway needs to be suppressed in order to initiate the 
WNT/PCP pathway and nephron elongation after MET establishment, 
mechanisms balancing this transition have been explored. MET failure and 
prolonged WNT/βcatenin activation was shown to provoke Wilms tumour and renal 
cysts formation (Qian et al, 2005). Inversin is a WNT signal regulator that was 
shown to reduce βcatenin levels by increasing proteasomal degradation of 
cytoplasmic dishevelled, moreover it was shown to promote βcatenin-independent 
WNT signal transduction (Simons et al, 2005). It has been speculated that inversin 
could signal through the primary cilium and that urine flow in early tubules can 
regulate the cellular response to WNT via the primary cilium (Simons et al, 2005). 
However, it appears that the WNT pathway signals through βcatenin, in a 
canonical way, until MET establishment. Subsequent nephron maturation requires 
a switch from the “canonical” to the “non-canonical” WNT pathway, which is 
essential for PCP-oriented cell division that needs βcatenin suppression.   
In conclusion, WNT signalling is critical for kidney organogenesis and it plays an 
active role from early inductive stages to later steps of tubular epithelial 
maturation. 
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5.3 WNT signalling alterations in the kidney: cystic disease 
 
Disorders associated with the development of cystic changes in the kidney are 
known as cystic kidney disease. Among these, polycystic kidney disease (PKD) is 
a genetic disorder caused by the progressive development of cysts in nephrons 
and collecting ducts, commonly leading to end-stage renal failure. PKD can be 
classified as two types: autosomal dominant PKD (ADPKD) and autosomal 
recessive PKD (ARPKD) (Harris & Torres, 2009). The genes responsible for 
ADPKD diseases are polycystic kidney disease gene 1 (PKD1) and polycystic 
kidney disease gene 2 (PKD2) encoding respectively for polycystin-1 and 
polycystin-2 (Harris & Torres, 2009). ARPKD is instead caused by mutations in the 
polycystic kidney and hepatic disease 1 (PKHD1) gene, which encodes the 
fibrocystin protein (FPC). In ADPKD, cysts arise slowly from any segment of the 
nephron and increase in number and dimension over time. However, other tissues 
are also affected by cysts formation, including liver and pancreas (Boletta & 
Germino, 2003). Conversely, ARPKD has an early and severe onset, and is 
associated with cyst development in kidneys and liver (Harris & Torres, 2009). The 
exact mechanism of how these proteins lead to PKD pathogenesis remains 
unclear, but recently many papers have been published evidencing new roles for 
such proteins. As an example, PC2 is a calcium-sensitive cation channel, and it 
can sense fluid flow in the renal epithelial cells (Nauli et al, 2003), whereas PC1 
and FPC may function as PC2 modulators (Nauli et al, 2003). There are significant 
evidence linking canonical WNT signalling to cystic renal disease development. 
First, PC1 was shown to regulate the canonical WNT response. Indeed, the C-
terminal PC1 region resulted in augment WNT/βcatenin signalling, and this was 
also observed in different types of  cancer cells, like  osteoblasts (Lancaster & 
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Gleeson, 2010; Zhang et al). These results were in contrast with more recent data 
revealing that the C-terminal part of PC1 is able to facilitate the nuclear 
accumulation of catenin, however transcription of the catenin downstream target 
genes was decreased. PC1 seems to inhibit WNT signalling by reducing the 
affinity between catenin and TCF (Lal et al, 2008). The inhibitory effects on 
canonical WNT signalling is also consistent with the observation that 
overexpression of c-Myc, a β-catenin/TCF-regulated oncogene, induces a renal 
cystic phenotype in transgenic mice, and it has been shown to be overexpressed 
in ADPKD and other renal diseases (Lal et al, 2008). Finally, this inhibitory effect 
was also observed with PC2 deletion in kidney cells, but in this case it was not 
clear if it was due to a direct effect of PC2 or through an indirect effect that PC2 
can have on PC1 (Kim et al, 2009). Interestingly, it was observed that cysts arise 
in animal models of PKD with complete or partial loss of polycystin proteins 
(Lantinga-van Leeuwen et al, 2007), but also with their overexpression (Thivierge 
et al, 2006), leading to the concept that the kidney is particularly sensitive to gene 
dosage. Also alterations in the regulation of the WNT signalling pathway have 
been demonstrated to be involved in the pathogenesis of cystic renal disease. For 
example, conditional WNT mutant mice such as mice with βcatenin 
overexpression or APC inactivation (Qian et al, 2005) revealed that canonical 
WNT pathway over-activation leads to cystic renal phenotypes, further supporting 
a role for WNT/catenin signalling in cystogenesis. However, contradictory results 
indicate that canonical WNT loss-of-function mutants also display renal cysts 
(Lancaster & Gleeson, 2010). Again, this suggests that canonical WNT/βcatenin 
must be delicately balanced in the kidney. 
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5.3.1 A kidney injury model 
The cystic diseases can have an early or a late onset. In the latter, patients do 
not exhibit symptoms until adulthood when the kidney is fully developed. 
Considering that cyst generation is strictly linked to the renal developmental 
stage, is possible that tubules pass through a “developing-like” state, thus re-
activating some of the developmental programs. Injury has been proposed as a 
cause of resetting developmental programs. Indeed, in a predisposed subject, as 
a PKD patient, injury can be sufficient to trigger the rapid development of the 
cystic disease (Lancaster & Gleeson, 2010). The activation of WNT signalling 
during injury has already been confirmed (Lin et al, 2010), but the relevance of 
WNT pathway in such condition is still an open question (Fig. 9) . 
 
 
From Lancaster et al., Trends in Molecular Medicine 2010 
Figure 9. Cyst formation during development and injury. 
The developing kidney tubule epithelium forms from the differentiation of mesenchymal precursor 
cells. This process is triggered by canonical WNT signalling, which induces pretubular 
aggregates, a cluster of cells that are epithelial progenitors. Subsequently, canonical WNT 
signalling must be turned off and non-canonical WNT signalling takes over to form the epithelium 
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and the polarized tubule structure. When injury occurs, this process or a similar one is reactivated 
and both canonical and non-canonical WNT signalling are again required for new tubule 
formation. Cyst formation results from abnormalities in any of these cellular processes during 
development or injury repair.  
 
 
5.4 WNT signalling alterations renal cancer 
 
Aberrant regulation of WNT pathway has emerged as a frequent theme in cancer. 
Indeed, it was shown that the proviral insertion of the Wnt1 gene into the mouse 
genome was leading to the development of mammary hyperplasia in mice (Nusse 
& Varmus, 1982).  Hyperactive WNT-catenin signalling was also observed in 
colorectal cancer (Korinek et al, 1997). APC inactivating mutations are associated 
with familial adenomatous polyposis (FAP), which can progress to colorectal 
carcinomas (Korinek et al, 1997), and mutations in APC and catenin are also 
observed in colorectal cancers of non-FAP patients (Anastas & Moon, 2013). As 
previously discussed, proper catenin regulation is essential in the kidney. 
catenin activating mutations are common events in Wilms tumour (Koesters et al, 
1999), and  mice with Apc gene inactivation in the kidney are prone to the 
development of Renal Cell Carcinoma (Sansom et al, 2005). Finally, mutations or 
alterations in the regulation of catenin have been identified in RCC patients (Kim 
et al, 2000). These data suggest that the activation of the catenin signalling 
pathway, which has been associated with several cancerous conditions (Anastas 
& Moon, 2013), may also play a role in RCC development.   
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AIM OF THE THESIS 
 
The aim of my PhD project was to identify molecular mechanisms/pathways that 
can be altered during overexpression/overactivation of the TFE transcription 
factors, which can drive carcinogenesis, and ideally to identify novel druggable 
targets.  To answer this question, we had to generate an experimental  animal 
system able to recapitulate the disease observed in TFE-fusion RCC patients.  
 
The specific aims of my PhD were: 
- To generate renal specific Tcfeb (murine Tfeb gene) overexpressing 
mouse lines. 
We generated both a constitutive and a tamoxifen-inducible kidney-
specific Tcfeb-overexpressing mouse line by crossing conditionally Tcfeb 
overexpressing mice with both a constitutive and an inducible KSPcdh16-
CRE (kidney-specific Cadherin16 CRE) mouse line. These mice 
developed both  cystic and cancerous renal pathologies. 
 
- To evaluate if the transgenic mouse lines recapitulated the pathology 
observed in TFEB-fusion RCC patients. 
Extensive histological analyses were performed to fully characterize both 
the cystic and cancerous renal phenotypes observed in the animal models 
to understand if these models resembled the human disease.  
 
- To identify altered molecular pathways. 
Microarray analysis was performed on newborn transgenic mice to identify 
altered molecular pathways, which were subsequently validated by 
quantitative real-time PCR. Biochemical and in-vitro assays were 
AIM OF THE THESIS 
 
72 
 
performed to demonstrate the relevance of the WNT pathway, which was 
found altered in the transcriptional analyses. Finally, Tcfeb-overexpressing 
mice were treated with a drug that inhibits the WNT pathway to 
understand the relevance of this pathway in renal cystic and cancerous 
disease development. Importantly, a significant regression of both 
diseases was demonstrated in the presence of WNT signalling inhibition. 
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MATERIALS AND METHODS 
 
 
 
Mouse models: 
CondTg-Tcfeb transgenic mice (generated by Dr. Settembre (Settembre et al, 
2011)) were crossed with KSPcdh16-CRE (Jackson laboratories) and 
indKSPcdh16-CRE (generated by Dr. Peters (Lantinga-van Leeuwen et al, 2006)) 
mice to obtain KSPcdh16/Tcfeb and indKSPcdh16/Tcfeb mice. The ATG7 
conditional KO mice (Komatsu et al, 2005) (ATG7 fl/fl mice) were a generous gift 
from T.Eissa. Mice were crossed with KSPcdh16-CRE and CondTg-Tcfeb mice to 
obtain kidney-specific ATG7 deletion and Tcfeb overexpression (ATG7-/-
;KSPcdh16/Tcfeb). All mice were mated starting from 8 weeks and were 
maintained in a C57BL/6 background genotype. To genotype all the mouse lines, 
tails were cut and lysed in 500μl lysis Buffer (50mM TrisHCl pH 8, 100mM EDTA, 
100 mM NaCl, SDS 1%), supplemented with 20μl proteinase K (20mg/ml) at 55°C 
O/N. After removal of cellular debris (5 min centrifugation at maximum speed), 
DNA was precipitated by adding 1 ml of 100% ethanol (EtOH) to each tube and 
gently mixed by inverting the tubes. Subsequently, DNA was washed once with 
70% EtOH air-dried and resuspended in 500μl H2O.  Mice were genotyped by 
PCR on the tail DNAs using specific primers: 
KSPcdh16-CRE-forward: 5’-GCA GAT CTG GCT CTC CAA AG-3’   
KSPcdh16-CRE-revers: 5’-AGG CAA ATT TTG GTG TAC GG-3’    
cotrolKSPcdh16-CRE-forward: 5’-CAA ATG TTG CTT GTC TGG TG-3’  
controlKSPcdh16-CRE-revers: 5’-GTC AGT CGA GTG CAC AGT TT-3’   
indKSPcdh16-CRE-forward: 5’-CATTCTCTCCCACTGAATGGA-3’ 
indKSPcdh16-CRE-revers-1: 5’-ACAGAGTGGGGTTTGTGTCTG-3’ 
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indKSPcdh16-CRE-revers-2: 5’-AACTGTCCCCTTGTCATACCC-3’ 
CondTg-Tcfeb-forward: 5’-TGAGAGAAGACGCAGGTTCA-3’   
CondTg-Tcfeb-revers: 5’-AATCACCGTCATGGTCTTTG-3’  
ATG7fl/fl-forward:  5’-TGGCTGCTACTTCTGCAATGATGT-3’  
ATG7fl/fl-revers: 5’- CAGGACAGAGACCATCAGCTCCAC-3’  
   
PCR conditions using the LA Taq mixture (Takara Bio Inc, Japan) were: 
- for KSPcdh16-CRE genotype: 
1. 94°C 3 min; 
2. 94°C 30 sec/65°C 1 min/72°C 1 min for 33 cycles; 
3. 72°C 3 min (final extension). 
 
- for indKSPcdh16-CRE genotype: 
1. 95°C 3 min; 
2. 95°C 30 sec/59°C 30 sec/72°C 1 min for 35 cycles; 
3. 72°C 3 min (final extension). 
 
- for CondTg-Tcfeb genotype: 
1. 95°C 3 min; 
2. 95°C 30 sec/61°C 30 sec/72°C 30 sec for 30 cycles; 
3. 72°C 3 min (final extension). 
 
- for ATG7-flox/flox genotype: 
1. 95°C 3 min; 
2. 98°C 30 sec/62°C 30 sec/72°C 1 min for 30 cycles; 
3. 72°C 7 min (final extension). 
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PCR products of the different PCRs are showed in figure 10.  
 
Figure 10. Genotypes of representative litters. 
Representative genotypes of KSPcdh16CRE, indKSPcdh16CRE, Tcfeb3xFLAG and ATG7fl/fl 
mice. In the KSPcdh16CRE PCR, lanes 1, 2 and 4 show KSPcdh16+/- animals (420 bp CRE band, 
200 bp wild-type band) . In the indKSPcdh16CRE PCR, lanes 1 and 2 indicate indKSPcdh16CRE+/- 
mice (507 bp CRE band, 388 bp wild-typet band) . In the Tcfeb-3xFLAG PCR, lanes 1, 4 and 5 
represent Tcfeb-3xFLAG+/- positive mice (700 bp band). In the ATG7fl/fl PCR lane 1 indicate a wild-
type animal (1,3kb wild type band), lane 2,3 and 5 are ATF7fl/fl animals (560 bp ATG7flox band), 
lane 4 is an ATG7flox/+ mouse ( 1.3 kb wild-type band, 560 bp ATG7flox band) (M, marker; B, 
Blank).  
 
For the tamoxifen injections, IndKSPcdh16+/-;wt and indKSPcdh16+/-;tgTcfeb+/- 
mice were weighted first, and then injected Intra-Peritoneally (IP) with tamoxifen at 
a dosage of 100 micrograms/gram of mouse weight for three consecutive days to 
obtain an efficient recombination.  
Experiments were conducted in accordance with the guidelines of the Animal Care 
and Use Committee of Cardarelli Hospital in Naples and authorized by the Italian 
Ministry of Health. 
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Tissue collection 
For all the tissue collection procedures, age-matched mice were weighted and 
then anesthetised with an IP injection of avertin at 2ml/100 gr. To collect kidney 
and liver samples, animals were perfused with PBS, pH 7,4, to completely clear 
blood from tissues. Pictures from kidneys and livers were taken. Both kidneys 
were weighted and then divided in two halves, one half from each kidney was 
frozen in dry ice and stored at -80ºC for molecular analyses, and the other ones 
were fixed in 4% paraformaldehyde (for immuno-staining). Regarding liver 
samples, a small piece was fixed in 4% paraformaldehyde and the remaining part 
was cut in small pieces and frozen in dry ice. 
 
Biochemical analysis: 
Blood samples were collected from the retro-orbital vein in heparinized tubes, and 
then centrifuged at 10,000 g for 10 min at 4ºC to obtain the plasma. Plasma was 
harvested and stored frozen until use. Plasma urea was measured using 
standardized clinical diagnostic protocols of the Academical Medical Center 
Amsterdam. Albumin (Bethyl Laboratories, Montgomery, TX) was measured in 
urines collected for 24h in metabolic cages and analysed in the Academical 
Medical Center with standardized procedures. The biochemical measurements 
were performed by Lotte Kors in the Academical Medical Center in Amsterdam. 
 
High Frequency Ultrasound and PET/CT scan analyses. 
All the imaging procedures were performed at the CEINGE institute in Naples, 
Italy, by Luigi Auletta. Mice were under general anesthesia. Anesthesia was 
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produced in an induction chamber, saturated with 5% isoflurane (Iso-Vet 1000 
mg/g Inhalation Vapor, Piramal Healthcare UK Ltd., Northumberland, UK) in 
oxygen (2 L/min) and subsequently maintained during all procedures with a 
conenose delivering isoflurane at 1.5% in oxygen at 2 L/min. 
For High Frequency Ultrasound, each mouse was placed in dorsal recumbency on 
a dedicated, heated, small animal table (VEVO Imaging Station 2, FUJIFILM 
VisualSonics, Inc., Toronto, Ontario, Canada) and hairs were removed with a 
small clipper and then with the application of a depilatory cream, and a pre-
warmed ultrasound-coupling gel was applied to the skin to improve ultrasound 
transmission and reduce contact artefacts. A 40 MHz transducer (MS 550 D, 
FUJIFILM VisualSonics, Inc., Toronto, Ontario, Canada) was mounted on the 
dedicated stand of the imaging station, and B-mode and Color-Doppler mode 
images were obtained on the ultrasound equipment (VEVO 2100, FUJIFILM 
VisualSonics, Inc., Toronto, Ontario, Canada).  
Positron emission tomography (PET) coupled with computed tomography (CT) 
was performed with a dedicated small animals PET/CT scanner (eXplore Vista, 
GE Healthcare), with a trans-axial field of view of 6.7 cm and an axial field of view 
of 4.8 cm. Animals, fasted overnight, were injected under general anesthesia in 
the lateral caudal vein with 300 µCi of [18F]-fluorodeoxyglucose (FDG). Mice were 
left to recover from anesthesia under a heating lamp and PET/CT acquisitions 
were started after 90 minutes of biodistribution. Static emission scans of 30 
minutes with energy window of 250–700 keV were acquired. The PET datasets 
were reconstructed by 2D FORE/3D OSEM algorithm and corrected for random 
coincidences, scatter, physical decay to the time of injection (voxel size: 
0.3875 × 0.3875 × 0.775 mm3). The mean specific uptake value (SUV) was 
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obtained for each region of interest using the visualization and analysis software of 
the scanner (version 4.11 Build 701, MMWKS Image Software: Laboratorio de 
Imagen, HGUGM, Madrid, Spain). 
 
Survival analysis: 
Survival curves were calculated for a period of 8 months on a total of 15 
KSPcdh16/Tcfeb mice, 10 indKSPcdh16/Tcfeb mice (Tam P12), 12 
indKSPcdh16/Tcfeb mice (Tam P14) and 12 indKSPcdh16/Tcfeb mice (Tam P30) 
grown in the same animal facility, all in same background (C57BL/6). Values were 
plotted by the product-limit method of Kaplan and Meier; statistical analyses were 
carried out applying the Log Rank (Mantel-Cox) test. 
 
Cell culture, transfections and plasmids: 
Primary kidney cells were obtained from P30 KSPcdh16+/-;wt and KSPcdh16+/-
;tgTcfeb+/- mice. Animals were first anesthetised as already described, and then 
sacrificed by cervical dislocation. Primary kidney cells were derived following the 
protocol described in Leemans et al. (Leemans et al, 2005). Kidneys were 
collected, uncapsulated and washed shortly in ethanol 70% and then PBS to 
prevent contaminations. Tissue from the outer cortex and inner medulla was cut 
into approximately 1mm3 pieces, washed in pre-warmed PBS and centrifuged at 
1200 rpm for three minutes. Kidney pieces were subsequently digested by 1mg/ml 
collagenase type 1A (Sigma-Aldrich) at 37°C for one hour and then filtered in 
40μm filters. Finally the cell suspension was washed with PBS, and spinned at 
1500 rpm for five minutes twice. Primary tubular epithelial cells (TECs) were grown 
to confluence in DMEM-F12 culture medium supplemented with 10% FCS, 
100IU/ml penicillin, 100mg/ml streptomycin, 2mM L-glutamine (Gibco; Invitrogen 
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Corp.), 1% ITSe (Thermo-Fisher) and 1% S1 hormone mixture (Sigma-Aldrich) 
and were cultured in 5% CO2 at 37 degrees. TECs were identified by characteristic 
cobblestone-shaped morphology.  
HEK293 and HK2 cells were purchased from ATCC. HEK293 cells were cultured 
in DMEM (Euroclone) supplemented with 10% FBS, 100IU/ml penicillin, 100mg/ml 
streptomycin and 2mM L-glutamine (Gibco; Invitrogen Corp.). HK2 cells were 
grown in DMEM-F12 (Invitrogen) supplemented with 5% FBS, 100IU/ml penicillin, 
100mg/ml streptomycin, 2mM L-glutamine (Gibco; Invitrogen Corp.) and 1% ITSe. 
Cells were grown at 5% CO2 at 37 degrees.  
Human full-length TFEB-FLAG was previously described (Settembre et al, 2011). 
The TopFlash and FopFlash plasmids (Upstate), the pCS2+MT-Myc-tagged β-
CATENIN (full-length β-CATENIN), and the Evr2-Tcf1E plasmid (Tcf1E) were 
kindly provided by Dr. M. Plateroti.  
Cells were transfected with Lipofectamine LTX and Plus reagent (Invitrogen) 
following the manufacturer’s protocol. Luciferase activity was measured 48h post-
transfection using the Dual-Luciferase Reporter Assay System (Promega). To 
normalize transfection efficiency in reporter assays, the HEK293 and HK2 cells 
were co-transfected with a plasmid carrying the internal control reporter Renilla 
reniformis luciferase driven by a TK promoter (pRL-TK; Promega). Data are 
representative of three independent experiments and statistical significance was 
determined using Student's t-test.  P<0.05 was considered as significant. 
 
In-vitro drug treatments and MTT proliferation assay: 
Cultured primary kidney cells derived from the cortex and medulla of KSPcdh16/wt 
and KSPcdh16/Tcfeb mice were seeded in 96-well plates at the density of 
5x103cells/well, maintained overnight at 37°C, and incubated in the presence of 
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the test compounds at the different concentrations.  PKF118-310 and CGP049090 
were added at different dosages (0µm, 0.2µm, 0.4µm, 0.8µm, 1.6µm, 3.2µm) for 
24 hours. 0µm represents the basal proliferation of cells after 48 hours of plating. 
MTT assay was used to assess cell proliferation. This assay is based on the 
protocol initially described by Mossmann (1983) and subsequently optimized for 
the cell lines used in these experiments. Briefly, 5mg of MTT powder was 
solubilized in 1mL of PBS and filtered. 10μL of this solution was added to 100μl of 
cell culture medium without phenol red. At the end of the incubation time, cells 
were washed twice with PBS and incubated with MTT-media solution to form 
formazan crystals. After four hours, media was removed and 100μl/well of a 
solubilisation solution was added to the cells (2.1mL HCl 10N, 500mL isopropanol) 
for four hours at 37°C to obtain a complete solubilisation of the crystals. As a 
readout, absorbance of the 96-well plate was measured recording the Optical 
Density (OD) at 570nm with a microplate spectrophotometer system. Results are 
representative of three independent experiments performed on three different 
KSPcdh16/wt and KSPcdh16/Tcfeb mice. T-test is referred to cells without drug 
(0µm) taken from KSPcdh16/Tcfeb mice versus cells without drug (0µm) taken 
from KSPcdh16/wt mice. Data are representative of three independent 
experiments and statistical significance was determined using Student's t-
test.  P<0.05 was considered as significant. 
 
In vivo drug treatments: 
P21 KSPcdh16/wt and KSPcdh16/Tcfeb mice were intraperitoneally injected daily, 
from Monday to Friday, with the PKF118-310 drug at the dose of 0.85mg/kg or 
with an equal amount of vehicle (DMSO). Mice were weighted every day from 
Monday to Friday. After 30 days from the beginning of the treatment, animals were 
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sacrificed and kidneys were collected, weighted and processed for further 
analyses. Six animals for each group and genotype were collected. 
 
Quantitative real-time PCR: 
Total RNA was isolated from frozen samples by adding 1ml of Trizol solution (Life 
Technologies) per piece, and lysed using a TissueLyser (Qiagen). After that, 200l 
of chloroform were added, tubes were shacked for 15 seconds and centrifuged to 
obtain three phases, a lower red phase, an interphase, and a colorless upper 
aqueous phase containing the RNA. The aqueous phase was collected and 500l 
of isopropanol were added to ensure RNA precipitation. After ten minutes, 
samples were centrifuged, the supernatants were removed and RNA pellets were 
washed with ethanol 75%, centrifuged, and then air-dried and resuspended in 30-
50l of RNase-free water. After complete RNA resuspension, 1g of the RNA 
solution was reverse transcribed to single-stranded cDNA by using QuantiTect 
Rev Transcription Kit (Qiagen) in a final reaction volume of 20l. cDNA mixes were 
diluted 1:3 in water, and 2l of the diluted cDNA solution was analysed by Real-
Time PCR. Real-time PCR was performed using SYBR Green (Roche 
Diagnostics) and performing the reaction in the LightCycler® System 2.0 (Roche 
Applied Science). The parameters of Real-time PCR amplification were defined 
according to Roche recommendations. To quantify gene expression, Gapdh 
mRNA expression was used as an internal reference. All the values are shown as 
fold activation respect to w-type levels. Data are representative of three 
independent experiments and statistical significance was determined using 
Student's t-test.  P<0.05 was considered as significant. 
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The following primers were used in this study:  Gapdh; forward (fw) 
tgcaccaccaactgcttagc, reverse (rev) tcttctgggtggcagtgatg; Tcfeb; fw 
gcagaagaaagacaatcacaa, rev gccttggggatcagcatt; Ccnd1; fw 
ccttgactgccgagaagttgtg, rev gttccacttgagcttgttcacca; Axin2; fw 
gatgcatcgcagtgtgaagg, rev ggttccacaggcgtcatctc; c-Myc; fw 
ccagcagcgactctgaagaa, rev acctcttggcaggggtttg; Fzd3; fw gcatctgggagacaacatgg, 
rev caggtctggacgactcatctg; Rnf146; fw agcggaggagaaaagactgc, rev 
acatagccctttctcggtccg; Kdm6a; fw tgacagcggaggagagggag, rev 
ccttcatcctggcgccatct; Cdkn1a; fw gtctgagcggcctgaagatt, rev caatctgcgcttggagtgat; 
HbEgf; fw tccacaaaccagctgctacc, rev ccttgtggcttggaggagaa; Pak1; fw 
ttcctgaaccgctgtcttga, rev tcaggctagagaggggcttg; Areg; fw tattggcatcggcatcgtta, rev 
tgcacagtcccgttttcttg; Crk; fw cgcgtctcccactacatcat, rev tctcctattcggagcctgga; Tgfa; 
fw agtgcccagattcccacact, rev cgtacccagagtggcagaca; Gpnmb, fw 
tggctacttcagagccacca, rev ggcatggggacatctgctat.  
 
Microarray hybridization: 
Microarray analysis was performed in collaboration with the Coriell Genotyping 
and Microarray Center, in Camden, New Jersey. Total RNA (3μg) was reverse 
transcribed to single-stranded cDNA with a special oligo (dT) 24 primer containing 
a T7 RNA promoter site, added 3' to the poly-T tract, prior to second strand 
synthesis (One Cycle cDNA Synthesis Kit by Affymetrix, Fremont, CA, USA). 
Biotinylated cRNAs were then generated, using the GeneChip IVT Labeling Kit 
(Affymetrix). 20μg of biotinylated cRNA was fragmented and 10μg hybridized to 
the Affymetrix GeneChip Mouse 430A_2 microarrays for 16 hours at 45°C using 
an Affymetrix GeneChip Fluidics Station 450 according to the manufacturer's 
standard protocols.  
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For the analysis at P0, the total RNA was extracted from the kidney of three 
KSPcdh16/Tcfeb mice and of two control KSPcdh16/wt mice. For the analysis at 
P14 total RNA was extracted from the kidney of three KSPcdh16/Tcfeb P14 mice 
and three control KSPcdh16/wt P14 mice. 
 
Microarray data processing: 
Microarray data processing were performed by Rossella De Cegli in Tigem, 
Naples, Italy. The data discussed in this publication have been deposited in NCBIs 
Gene Expression Omnibus (GEO) (Edgar et al, 2002) and are accessible through 
GEO Series accession number GSE62977 (KSP_P0 dataset) and GSE63376 
(KSP_P14 dataset). Low-level analysis to convert probe level data to gene level 
expression was performed using Robust Multiarray Average (RMA) implemented 
using the RMA function of the Bioconductor project (Gentleman et al, 2004). 
 
Statistical analysis of differential gene expression: 
For each gene, a Bayesian t-test (Cyber-t) (Baldi & Long, 2001) was used on RNA 
normalized data to determine if there was a significant difference in expression 
between KSPcdh16/Tcfeb mice versus KSPcdh16/wt  mice both at P0 
(GSE62977-KSP_P0 dataset) and at P14 (GSE63376-KSP_P14 dataset). P-value 
adjustment for multiple comparisons was done with the False Discovery Rate 
(FDR) of Benjamini-Hochberg (Klipper-Aurbach et al, 1995). The threshold for 
statistical significance chosen was FDR≤0.05. In the KSP_P0 dataset we selected 
361 probe-sets corresponding to 294 significantly induced genes (GSE62977). In 
the KSP_P14 dataset we selected 729 probe-set corresponding to 628 genes 
(GSE63376). 
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(Immuno-) histological analysis: 
All the tissues were embedded in paraffin. Immediately after dissection, tissues 
were stored O/N in 4% paraformaldehyde and then they underwent to an 
ascending scale of alcohols for complete dehydration. They were kept one hour in 
ethanol 70%, one hour in ethanol 80%, one hour in ethanol 95%, one hour in 
ethanol 100% and O/N in a second wash of ethanol 100%. The day after they 
underwent to two washes of 1 hour each of Xylene, three washes of paraffin and 
then they were included. For all the staining and immunohistochemistry 
procedures, 4µm tissue sections were first de-paraffinized with a descending scale 
of alcohols, and then they were analysed using standard hematoxylin and eosin 
(HE) staining, periodic acid Schiff (PAS) staining, Sirius Red (SR) staining, or 
immunohistochemistry. Some of these stainings were performed in collaboration 
with Prof. Dorien Peters at the Leiden University Medical Center in Netherlands, 
as specified in the figure legends.  For the HE staining, tissue sections were 
stained with haematoxylin for two minutes, then rinsed in running tap water, rapidly 
dipped 8-10 times in acid ethanol (1% HCl in 70% ethanol) to allow de-staining, 
rinsed in running tap water, and then in deionized water, finally stained in eosin for 
five minutes, dehydrated and mounted with Eukitt. For the PAS-D procedure, 
tissue sections were brought to distilled water, and then digested 30 minutes with 
0,25%  diastase (alpha-amylase). After that sections were washed with RX water 
and stained following the standardized protocol (BIOPTIKA), dehydrated and 
mounted with Eukitt. For staining with Sirius Red de-paraffinized sections were 
incubated in 0.2% phosphomolybdic acid hydrate for five minutes and 0.1% Sirius 
red for 90 minutes. Subsequently sections were incubated for one minute in 
saturated picric acid and then placed in 70% ethanol, dehydrated and mounted 
with Eukitt. For immunohistochemistry procedures, sections were subjected to 
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heat mediated antigen retrieval procedure (10mM citrate buffer pH 6.0) followed by 
1hr preincubation with normal goat serum (1:200; DakoCytomation, Glostrup, 
Denmark). After blocking of endogenous peroxidase activity for 15 minutes in 0.1% 
H2O2 in water, sections were incubated with primary antibodies diluted in 1% BSA 
in PBS. Then sections were washed three times in PBS, and incubated for 30 
minutes with the secondary antibody. Immune reactions were revealed using 
NovaRed or diaminobenzidine chromogen and counterstained with haematoxylin 
diluted 1:10 in RX water. Sections were washed five minutes in running tap water, 
dehydrated, and mounted with Eukitt. 
Primary antibodies: rabbit polyclonal anti-megalin (1:750, Pathology LUMC, 
Leiden, the Netherlands), goat polyclonal anti-uromodulin (1:4000, Organon 
Teknika-Cappel, Turnhout, Belgium), rabbit polyclonal anti-aquaporin-2 (1:4000 
Calbiochem, Amsterdam, The Netherlands), rabbit polyclonal anti-βcatenin (1:500, 
Santa Cruz sc-7199), rabbit monoclonal anti-active-βcatenin (1:800, Cell Signaling 
#8814), rabbit polyclonal anti-cadherin16 (1:300, Novus NBP1-59248), rabbit 
polyclonal anti-ATG7 (1:300, Santa Cruz sc-33211), rabbit monoclonal anti-Ki67 
(ABCAM ab16667, clone SP6, 1:200), a rabbit polyclonal anti-PAX8 antibody 
(Proteintech, 10336-1-AP, 1:1000) and a mouse monoclonal anti-Cytokeratin 7 
(Abcam, ab9021, 1:500). Secondary antibodies: anti-rabbit envision HRP 
(DakoCytomation, Glostrup, Denmark), rabbit-anti-goat HRP (1:100), power rabbit 
poly-HRP (Biocare Medical, M4U534L).  
 
Quantitative histology: 
Histomorphometric analysis was conducted on PAS and Ki67-stained sections and 
were performed in collaboration with Dr. Giovanni Bertalot at the European 
Institute of Oncology (IEO), Milan, Italy. For the cyst characterization, cyst number 
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and area was calculated on PAS sections from three animals per genotype and 
group.  Cysts were hand-annotated and measured in the outer and inner cortex, 
and the outer and inner medulla. Finally, they were sub-divided according to their 
size. For the analyses performed on the drug- and vehicle-treated animals, the 
analysis was conducted on Ki67-stained sections. The number and size of the 
cysts were defined within the areas identified by the pathologist using ImageScope 
(Leica-Biosystems Nussloch GmbH). Using the same method, the number of 
papillae was counted and the proportion of Ki67 positive nuclei on the total number 
of nuclei within the papillae was calculated. For these analyses, a total of six 
KSPcdh16/Tcfeb vehicle (DMSO)-treated and six KSPcdh16/Tcfeb drug (PKF118-
310)-treated animals were evaluated.  
 
Antibodies and Western blotting: 
Cells or tissues were lysed in ice-cold lysis buffer (50mM Tris at pH 7.9, 1% Triton 
X-100, 0,1% Tween 20, 150mM NaCl, 5mMMgCl2, 10% glycerol) containing 
phosphatase (Roche) and protease (Sigma) inhibitors. Tissue pieces were 
disrupted using a TissueLyser (Qiagen) whereas cells were collected by scraping 
the plates. Samples were lysed in lysis buffer for 1 hour in ice and then centrifuged 
at 14000 rpm for 15 minutes at 4°C to eliminate cells debris.  Protein concentration 
was measured by using colorimetric Bradford method (Bio-rad). Samples were 
mixed with Laemmli lysis buffer containing β-mercaptoethanol, boiled and resolved 
by SDS-PAGE. Electrophoresis was run at 80V constant. Thereafter, proteins 
were blotted onto polyvinylidene fluoride (PVDF) membranes and blocked for 1 
hour with non-fat 5% milk or 5% BSA diluted in 1X TBS, 0,1% Tween 20, 
according to the primary antibody protocol. Membranes were incubated with 
primary antibodies overnight at 4°C. The next day membranes were washed three 
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times in TBS/0,1%, Tween 20 and incubated with corresponding HRP-labelled 
secondary antibodies (Calbiochem). Finally, protein visualisation was performed 
using the enhanced chemiluminescence (ECL) (Perkin Elmer, Waltham, MA, 
USA). Membranes were developed using a Chemidoc UVP imaging system (Ultra-
Violet Products Ltd) and densitometric quantification was performed in unsaturated 
images using ImageJ (NIH).  
For Western blots, the following antibodies were used: anti-FLAG M2-HRP 
(Sigma, cat. A8592, 1:1000), anti-actin (Sigma, cat. A2066, 1:5000), anti-βtubulin 
(Sigma, cat. T8328, 1:1000), anti-Human/Mouse/Rat Pan-Akt (R&D, cat. 
MAB2055, 1:500), Phospho-Akt (Ser473) (D9E) (Cell Signaling, cat. #4060, 
1:1000), anti-human, mouse, and rat ERK1/ERK2 (R&D, cat.216703, 1:2000), 
anti-Human/Mouse/Rat Phospho- ERK1(T202/Y204)/ERK2 (T185/Y187) (R&D, 
cat. AF1018, 1:1000), anti-βcatenin (BD, cat. 610154, 1:500), anti-non phospho 
active βcatenin (Cell Signaling, cat. #8814, 1:1000), anti-Cyclin D1 (Cell Signaling, 
cat. # 2978, 1:1000), anti-LRP6 (Cell Signaling, cat. #3395, 1:1000), anti-phospho-
LRP6 (Ser1490) (Cell Signaling, cat. #2568, 1:1000), anti-GSK3β (Cell Signaling, 
cat. #9315, 1:1000), anti-phospho-GSK3β (Ser9) (Cell Signaling, cat. #9323, 
1:1000). 
 
Statistical Analysis: 
GraphPad Prism (GraphPad Software, San Diego, CA) was used for all statistical 
analysis. Statistical analyses of data were performed using Student’s t-test.  One-
way ANOVA and Tukey’s post-hoc tests were performed when comparing more 
than two groups relative to a single factor (time or treatment/genotype). Two-way 
and three-way ANOVA and Tukey’s post-hoc tests were performed when 
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comparing more than two groups relative to two or more factors. Mantel-Cox test 
was used for the survival analysis. P<0.05 was considered significant.  
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RESULTS 
 
 
 
1. Generation of the transgenic mouse lines 
To study the mechanisms underlying tumour development in TFEB-fusion RCC, 
we generated transgenic mouse lines that specifically overexpress TFEB in the 
kidney. We crossed a previously generated Tcfeb conditional overexpressing 
mouse line that carries Tcfeb-3xFlag under the control of a strong chicken beta-
actin (CAG) promoter (Settembre et al, 2011), herein referred to as CondTg-Tcfeb, 
with the KSPcdh16-CRE mouse line, in which the CRE recombinase is specifically 
expressed in renal tubular epithelial cells starting from embryonic stage E12.5 
(Shao, 2002). In addition, to assess the effects of Tcfeb overexpression during 
kidney development, we generated a second transgenic line by crossing the 
CondTg-Tcfeb mice with a mouse line that carries a tamoxifen-inducible CRE-
ERT2 element under the control of a KSPcdh16 promoter (IndKSPcdh16CRE 
promoter) (Lantinga-van Leeuwen et al, 2006) (Fig. 11).  
 
 
Figure 11. Map of the generation of the transgenic mouse lines with kidney-specific Tcfeb 
overexpression. 
Map of the transgene: Tcfeb-3XFLAG was inserted after the chicken actin promoter (CAG) and the 
chloramphenicol acetyltransferase (CAT)-SV40pA flanked by loxP sites. The latter can be removed 
by CRE recombinase, resulting in the overexpression of the Tcfeb gene under the control of the 
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strong CAG promoter. Two different CRE lines were used: 1) a constitutive kidney-specific 
KSPcdh16 (Cadherin 16) CRE and 2) a tamoxifen-inducible indKSPcdh16.  
 
KSPcdh16+/-/CondTg-Tcfeb+/- and indKSPcdh16+/-/CondTg-Tcfeb+/- double 
heterozygous mice, henceforth referred to as KSPcdh16/Tcfeb and 
IndKSPcdh16/Tcfeb mice, respectively, were generated from these crossings. We 
checked both the constitutive and inducible lines for renal Tcfeb overexpression 
and confirmed that Tcfeb mRNA levels were progressively increased over time 
(Fig. 12A). Consistently, immunoblot experiments revealed increased levels of 
Tcfeb-3xflag protein in kidneys from KSPcdh16/Tcfeb and IndKSPcdh16/Tcfeb 
mice (Fig. 12B).  
 
 
Figure 12. Assessment of Tcfeb overexpression in the transgenic mouse lines. 
A) Real-time PCR analysis of Tcfeb-3xFLAG mRNA levels performed on KSPcdh16/wt and 
KSPcdh16/Tcfeb mice at different stages (P0, P12, P30) and on indKSPcdh16/wt and 
indKSPcdh16/Tcfeb mice induced with tamoxifen at P12 and sacrificed at P90. Values are shown 
as the average (± SEM) of three animals per time point and genotype (* P <0 .05, ** P < 0.01, two-
sided, Student’s t test). B) Immunoblot analysis using an anti-Flag antibody to determine the 
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expression of Tcfeb-3xFLAG protein in KSPcdh16/Tcfeb and Tam-treated indKSPcdh16/Tcfeb 
mice.  
 
2. Progressive cystic pathology in transgenic mouse lines 
At sacrifice, kidneys from adult KSPcdh16/Tcfeb and tamoxifen-treated 
IndKSPcdh16/Tcfeb mice completely filled the abdominal cavity (Fig. 13).  
 
 
Figure 13. Renal Tcfeb overexpression results in a severe kidney enlargement. 
Representative images of the abdominal cavity of KSPcdh16/wt, KSPcdh16/Tcfeb and Tam-treated 
indKSPcdh16/Tcfeb mice at P90. 
 
KSPcdh16/Tcfeb mice started to enlarge at P12, but a sensible increase in size 
and Kidney to Body Weight (KW/BW) ratio was observable at P30 (Fig. 14A, B) 
and continued over time.  
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Figure 14. Quantification of kidney enlargement  over time.  
Kidney to body weight ratio (KW/BW) was calculated on KSPcdh16/wt and KSPcdh16/Tcfeb mice 
at different stages (P=days post-natal). A) Pictures of kidneys from KSPcdh16/wt and 
KSPcdh16/Tcfeb mice. B) Relative KW/BW ratio on P0, P12, P30 and P90 mice. Data from males 
(M) and females (F) are shown separately as means of KSPcdh16/Tcfeb to KSPcdh16/wt KW/BW 
ratio. C) KW/BW ratio of P0, P12, P30 and P90 mice. Three-way Anova was applied (factors: 
gender, time, genotype) (* P <0 .05, ** P < 0.01,  *** P < 0.001). KW/BW data are relative to: 7 
KSPcdh16/wt and 3 KSPcdh16/Tcfeb males at P12, 9 KSPcdh16/wt and 6 KSPcdh16/Tcfeb 
females at P12, 4 KSPcdh16/wt and 4 KSPcdh16/Tcfeb males at P30, 8 KSPcdh16/wt and 9 
KSPcdh16/Tcfeb females at P30, 3 KSPcdh16/wt and 4 KSPcdh16/Tcfeb males at P90, 4 
KSPcdh16/wt and 4 KSPcdh16/Tcfeb females at P90, 3 KSPcdh16/wt and 3 KSPcdh16/Tcfeb 
males at P150, 3 KSPcdh16/wt and 3 KSPcdh16/Tcfeb females at P150. 
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A severe enlargement of the kidneys and a significant increase in the Kidney to 
Body Weight (KW/BW) ratio were also observed in IndKSPcdh16/Tcfeb mice 
induced with tamoxifen at several developmental stages (P12, P14, P30) (Fig. 
15A, B), even if a less severe increase in the KW/BW ratio was observed in mice 
induced at P30 (Fig. 15B, C).  
 
Figure 15. Quantification of renal enlargement in IndKSPcdh16/Tcfeb mice. 
A) Tamoxifen injection of IndKSPcdh16/Tcfeb mice at P12, P14 and P30 with representative 
images at the time of sacrifice (Tam, tamoxifen). B) Relative ratio of kidney to body weight 
(KW/BW) evaluated in Tam-treated IndKSPcdh16/Tcfeb mice at P90. C) KW/BW ratio of Tam-
treated IndKSPcdh16/Tcfeb mice at P90. Two-way Anova was applied (factors: treatment, 
genotype). KW/BW data are relative to: 6 IndKSPcdh16/wt and 5 IndKSPcdh16/Tcfeb mice injected 
with tamoxifen at P14 and sacrificed at P90, and 11 IndKSPcdh16/wt  and 8 IndKSPcdh16/Tcfeb 
mice injected with tamoxifen at P30 and sacrificed at P90. 
 
Survival time of KSPcdh16/Tcfeb mice was approximately 3 months (Fig. 16). 
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Interestingly, a late induction of Tcfeb overexpression in IndKSPcdh16/Tcfeb mice 
resulted in a slower development of the phenotype, with less severe kidney 
enlargement and an overall increase in the survival rate (Fig. 16).  
 
Figure 16. Evaluation of the survival time. 
Evaluation of the survival of KSPcdh16/Tcfeb and Tam-treated indKSPcdh16/Tcfeb mice. Survival 
curves were calculated for a period of 8 months on a total of 15 KSPcdh16/Tcfeb mice, 10 
indKSPcdh16/Tcfeb mice (Tam P12), 12 indKSPcdh16/Tcfeb mice (Tam P14) and 12 
indKSPcdh16/Tcfeb mice (Tam P30). Mantel-Cox test was applied (indKSPcdh16/Tcfeb Tam 
P12/Tam P14 p-value 0.02; indKSPcdh16/Tcfeb Tam P12/P30 p-value <0.0001) 
 
Renal function from KSPcdh16/Tcfeb and IndKSPcdh16/Tcfeb mice was severely 
affected, as observed by the strong increase in blood urea and albuminuria (Fig. 
17).  
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Figure 17. Renal-specific Tcfeb overexpression results in renal failure. 
(A) Blood urea and albuminuria levels in (B) KSPcdh16/Tcfeb and (C) indKSPcdh16/Tcfeb mice. 
Values are shown as means (± SEM) of at least three KSPcdh16/Tcfeb and indKSPcdh16/Tcfeb 
mice and are normalized versus the control animals (KSPcdh16/wt and indKSPcdh16/wt). Blood 
urea was calculated on 3 KSPcdh16/wt and 4 KSPcdh16/Tcfeb animals, albuminuria was 
calculated on 8 KSPcdh16/wt and 6 KSPcdh16/Tcfeb animals and on 5 indKSPcdh16/wt and 3 
indKSPcdh16/Tcfeb mice. These biochemical analyses were performed by Dr. Lotte Kors in the 
Amsterdam Medical Center. 
 
High frequency ultrasound on transgenic animals revealed the presence of a 
severe cystic disease (Fig. 18).  
  
 
Figure 18. Ultrasound analysis shows the presence of cysts in kidneys. 
High-frequency ultrasound (HFUS) images of kidneys from P30 KSPcdh16/wt and 
KSPcdh16/Tcfeb mice. This analysis was performed at CEINGE institute in collaboration with Prof. 
Marco Salvatore. 
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An extensive histological examination was performed on the animals to 
characterize the cystic disease. In KSPcdh16/Tcfeb mice small cysts arose mainly 
from the cortex and outer medulla at P12 and became significantly enlarged at 
P30. At P90 kidney architecture was completely disrupted by cysts (Fig. 19A, B). 
IndKSPcdh16/Tcfeb mice induced at P12 with tamoxifen and sacrificed at P90 
showed a higher number of smaller cysts in both cortex and outer medulla (Fig. 
19A, B) 
 
 
 
Figure 19. Histological characterization of the cystic disease. 
A) Haematoxylin and Eosin (HE) staining of kidneys. Enlarged panels show cyst growth over time. 
B) Number (left graph) and area (right graph) of kidney cysts in KSPcdh16/Tcfeb, and 
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indKSPcdh16/Tcfeb mice. Number of cysts is shown as an average (±SEM) with bars sub-divided 
according to the dimension of the cysts. Cyst areas are presented as independent values (dots) 
with lines representing the means. Three-way (cyst number) and two-way (cyst area) Anova was 
applied. Cor, cortex; oMed, outer medulla; iMed, inner medulla. Data are shown as the average (± 
SEM) of three KSPcdh16/Tcfeb and indKSPcdh16/Tcfeb mice per time point (* P <0 .05, ** P < 
0.01,  *** P < 0.001). 
 
Cysts were also observed in IndKSPcdh16/Tcfeb induced at P14 and, to a lesser 
extent, at P30 (Fig. 20).  
 
Figure 20. Severity of the cystic disease is dependent from the time of induction of Tcfeb 
overexpression. 
Pictures and PAS stained section from Tam-treated IndKSPcdh16/Tcfeb mice at P90. In the Tam 
P14 group, 4 IndKSPcdh16/wt and 3 IndKSPcdh16/Tcfeb mice were analysed, in the Tam P30 
group, 5 IndKSPcdh16/wt and 3 IndKSPcdh16/Tcfeb mice  were analysed. 
 
Tubular epithelial cells lining the cysts showed high levels of cadherin 16, 
indicating the presence of KSPcdh16-CRE-mediated Tcfeb overexpression in 
these cells (Fig. 21).  
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Figure 21. Cadherin16 (CDH16) staining of kidneys from Tcfeb overexpressing mice. 
CDH16 immunohistochemistry (IHC)  on kidneys from P30 KSPcdh16/Tcfeb mice. The staining 
was performed on 4 KSPcdh16/wt and 3 KSPcdh16/Tcfeb P30 mice 
 
Histological analysis revealed that cysts from KSPcdh16/Tcfeb mice were positive 
for AQP2 and THP and negative for megalin, indicating that they originate from 
collecting ducts and distal tubules and not from proximal tubules. Notably, the 
largest cysts were almost completely negative to all tubular markers, suggesting 
that they became undifferentiated (Fig. 22).  
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Figure 22. Characterization of cyst origin in KSPcdh16/Tcfeb and indKSPcdh16/Tcfeb mice 
IHC staining of megalin, THP and AQP2 at different time points. Insets are enlargements of 
representative areas of interest. Larger cysts (denoted by an asterisk) are negative for all the 
markers tested. DTcy=Distal Tubules cysts; CDcy=Collecting Ducts cysts. These IHC stainings 
were performed on 3 mice per time-point and genotype and were done in collaboration with Prof. 
Dorien Peters at Leiden University Medical Center. 
 
Conversely, cysts from IndKSPcdh16/Tcfeb mice were positive to megalin and 
THP, indicating that they arose from proximal and distal tubules (Fig. 22, 23).  
 
 
Figure 23. Characterization of cyst origin in indKSPcdh16/Tcfeb mice.  
Megalin, THP and AQP2 stainings in P90 indKSPcdh16/Tcfeb mice. These stainings were 
performed on 4 IndKSPcdh16/wt and 3 IndKSPcdh16/Tcfeb mice (Tam P14), and on 5 
IndKSPcdh16/wt and 3 IndKSPcdh16/Tcfeb mice (Tam P30). 
RESULTS 
 
101 
 
 
Cysts were lined by either a single layer-flattened cuboidal epithelium (sCy), or by 
a multilayer epithelium (mCy), indicating a de-regulation of tubular cell proliferation 
(Fig. 24). We also noticed the presence of very enlarged cells with a clear 
cytoplasm, which are commonly known as Clear Cells (CCs) (Krishnan & Truong, 
2002) (Fig. 24). Sirius Red staining showed the presence of fibrosis and protein 
casts and revealed a significant accumulation of collagen inside the affected 
kidneys, as well as the presence of regions surrounded by multi-layered basement 
membranes (mBM) (Fig. 24). Importantly, the presence of Clear Cells, fibrosis and 
mBMs are characteristic features of kidneys from human patients with TFEB-
fusion RCC (Rao et al, 2012). 
 
Figure 24. PAS and Sirius Red staining 
 PAS staining shows the presence of single-layered or multi-layered cysts, and the presence of 
Clear Cells (CCs). SR staining shows areas of interstitial fibrosis, multi-layered basement 
membrane and protein casts. These IHC stainings were performed in collaboration with Prof. 
Dorien Peters at Leiden University Medical Center. Asterisks, protein casts; sCy, simple Cysts; 
mCy, multilayered Cy; IF, Interstitial Fibrosis; mBM, multi-layered Basement Membrane. 
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3. Identification of papillary Renal Cell Carcinoma and of liver 
metastases 
18F-FDG PET analysis showed a higher glucose consumption in the kidneys of 
transgenic animals compared to controls, indicating a higher rate of glucose 
metabolism and suggesting a neoplastic transformation (Fig. 25).  
 
Figure 25. FDG-PET analysis on KSPcdh16/Tcfeb mice revealed an increased renal glucose 
consumption. 
18F-FDG PET/CT scan on P30 KSPcdh16/Tcfeb mice. This analysis was performed at CEINGE 
institute in collaboration with Prof. Marco Salvatore. 
 
 
Similarly with PET analysis, HE and Ki67 stainings of the kidneys of 
KSPcdh16/Tcfeb mice revealed progressive cellular hyperproliferation, which 
evolved into Ki67-positive neoplastic papillae at 5 months (Fig. 26).  
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Figure 26. HE and Ki67 staining showed renal neoplastic lesions. 
HE and Ki67 staining performed on KSPcdh16/Tcfeb mice at P1, P12, P30 and 5 months. 
Beginning at P12 the increase in cyst size is associated with an increase in papillary proliferation 
that becomes completely neoplastic by 5 months. NP, Neoplastic Papillae. This analysis was 
performed in collaboration with Prof. Di Fiore at IEO (European Institute of Oncology). The 
oncologic characterization was done in collaboration with Dott. Bertalot at IEO. 
 
Neoplastic nodules, micropapillae and Hobnail-like cells, and mitotic spindles were 
detected at P12, 1 month, and 5 months, respectively (Fig. 27A-D). Focal 
microcalcifications (Fig. 27E), together with Clear Cells, and nests of neoplastic 
cells (Fig. 27F) were also detected in IndKSPcdh16/Tcfeb mice.  
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Figure 27. Histological characterization of the renal neoplasia. 
A-F) Representative images of neoplastic lesions at different stages: A) neoplastic nodules 
(arrows) in P12 KSPcdh16/Tcfeb mice; (B) micropapillae (arrows) and (C) hobnail-like cells 
(arrows) in P30 KSPcdh16/Tcfeb mice; D) mitotic spindles (arrows) in 5 month-old 
KSPcdh16/Tcfeb mice; E) microcalcifications (asterisk) in Tam-treated indKSPcdh16/Tcfeb mice 
induced at P14 and sacrificed at 5 months; F) neoplastic nests (NN) and clear cells (CCs) in Tam-
treated indKSPcdh16/Tcfeb mice induced at P12 and sacrificed at P90. This analysis was 
performed in collaboration with Prof. Di Fiore at IEO (European Institute of Oncology). The 
oncologic characterization was done in collaboration with Dott. Bertalot at IEO. 
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Figure 28. Invasion of the renal neoplasia 
HE staining of neoplastic lesions invading the surrounding stroma (arrows) in KSPcdh16/Tcfeb and 
indKSPcdh16/Tcfeb mice. This analysis was performed in collaboration with Prof. Di Fiore at IEO 
(European Institute of Oncology). The oncologic characterization was done in collaboration with 
Dott. Bertalot at IEO. 
 
Kidneys from both KSPcdh16/Tcfeb and indKSPcdh16/Tcfeb mice presented 
numerous neoplastic lesions with both solid and cystic aspects, ranging from 
0.102 to 2.93 mm and sometimes showing local invasion of the surrounding 
stroma (Figure 28). These features were observed on a total of 43 mice. 
Most importantly, liver metastases ranging from 0.9 to 3.8 mm, were found in both 
KSPcdh16/Tcfeb and indKSPcdh16/Tcfeb mice. In KSPcdh16/Tcfeb animals 
metastases were detected starting from P90 with an incidence of 23% (5 cases 
out of 21 KSPcdh16/Tcfeb mice older than three months).  These metastases 
were positive for the renal markers PAX8 and CDH16, while they were negative for 
the cholangiocarcinoma marker Cytokeratin 7 (CK7), consistent with their renal 
origin (Fig. 29). 
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Figure 29. Liver metastases were observed in older animals. 
Liver metastases in 5 month-old KSPcdh16/Tcfeb mice stained for HE, Ki67, PAX8 and CK7. Liver 
metastases were detected in 5 cases out of 21 KSPcdh16/Tcfeb mice older than three months. 
This analysis was performed in collaboration with Prof. Di Fiore at IEO (European Institute of 
Oncology). The oncologic characterization was done in collaboration with Dott. Bertalot at IEO. 
 
 
 
4. TFEB overexpression results in the induction of the canonical 
WNT pathway 
To characterize the molecular mechanisms and identify the relevant pathways 
necessary for tumour development, we performed transcriptome analysis on 
kidney samples from KSPcdh16/Tcfeb and KSPcdh16/wt mice at P0 (GSE62977-
KSP_P0 dataset) and at P14 (GSE63376-KSP_P14 dataset) (see materials and 
methods) and found that Tcfeb overexpression perturbed the kidney transcriptome 
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in a statistically significant manner (see material and methods, “Microarray data 
processing” section).  
 
Targeted analysis of the transcriptomic data revealed a significant induction of 
genes belonging to both ErbB and WNT signalling pathways (Table 3A, B).  
 
 
Table 3. List of ErbB and WNT-related genes belonging to the P0 and P14 microarray 
dataset. 
A)  List of 6 genes with a known role in ErbB signalling pathway which are significantly up-
regulated (FDR≤0.05) following TFEB overexpression in KSP_P0 microarray dataset (GSE62977) 
(upper table). One gene with a known role in ErbB signalling pathway which is significantly up-
regulated (FDR≤0.05) following TFEB overexpression in KSP_P14 microarray dataset (GSE62977) 
(lower table). B) List of 4 genes with a known role in WNT signalling pathway which are significantly 
up-regulated (FDR≤0.05) following TFEB overexpression in KSP_P0 microarray dataset 
(GSE62977) (upper  table). List of 10 genes with a known role in WNT signalling pathway which 
are significantly up-regulated (FDR≤0.05) following TFEB overexpression in KSP_P14 microarray 
dataset (GSE63376) (lower table). 
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First, data from the targeted analysis performed on the KSP_P0 dataset were 
validated on KSPcdh16/Tcfeb mice at several developmental stages (P0, P12, 
P30) by real-time PCR (Fig. 30A, B). Moreover, considering the relevance of WNT 
pathway alteration in development of the renal cystic pathology, we assessed its 
activation status by looking at the transcriptional levels of c-Myc and Axin2 genes, 
which are, together with Ccnd1, well-established WNT direct gene targets 
(Clevers, 2006b). Real-time PCR performed on KSPcdh16/Tcfeb animals at 
different developmental stages also showed the induction of these genes (Fig. 
30B).  
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Figure 30. Transcriptional validation of the microarray data. 
Transcriptional analyses were performed on KSPcdh16/wt and KSPcdh16/Tcfeb mice. A,B)  Tables 
show the relative increase of genes related to the ErbB (A) and WNT (B) pathways in the 
microarray analyses performed on kidneys from P0 KSPcdh16/Tcfeb mice. Graphs show Real-time 
PCR validations performed on kidneys from KSPcdh16/Tcfeb mice at different stages (P0, P12, 
P30). Data are shown as the average (± SEM) of three KSPcdh16/Tcfeb mice normalized versus 
wild type mice (± SEM) (* P <0.05, ** P < 0.01, *** P < 0.001, two-sided, Student’s t test). 
 
RESULTS 
 
110 
 
Kidneys from IndKSPcdh16/Tcfeb mice were also screened for their transcriptional 
profile, to check whether the same molecular alterations were also observed there. 
We validated the induction of all the genes belonging to the WNT pathway on 
IndKSPcdh16/Tcfeb mice induced with tamoxifen at P14 and at P30 (Fig. 31A, B). 
 
Figure 31. WNT transcriptional profile in indKSPcdh16/Tcfeb mice. 
Transcriptional analysis of previously validated genes belonging to the WNT pathway  on  P90 
indKSPcdh16/Tcfeb mice induced with tamoxifen respectively at P14 (A) and P30 (B). Data are 
shown as the average (± SEM) of three indKSPcdh16/Tcfeb mice and values are normalized to the 
wild type line. (* P <0.05, ** P < 0.01, *** P < 0.001, two-sided Student’s t test).  
 
Regarding the genes belonging to the ErbB pathway, the transcriptional response 
was more variable. We confirmed the induction of HbEgf, TgfAreg and 
Cdkn1but not of Crk and Pak on IndKSPcdh16/Tcfeb mice induced with 
tamoxifen at P14 (Fig. 32A), whereas we found an increase in HbEgf,Areg, 
Cdkn1and Pak mRNA levelsbut not of Tgf and Crk on IndKSPcdh16/Tcfeb 
mice induced with tamoxifen at P30 (Fig. 32B).  
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Figure 32. ErbB transcriptional profile in indKSPcdh16/Tcfeb mice. 
Transcriptional analysis of previously validated genes belonging to the ErbB pathway  on  P90 
indKSPcdh16/Tcfeb mice induced with tamoxifen respectively at P14 (A) and P30 (B). Data are 
shown as the average (± SEM) of three indKSPcdh16/Tcfeb mice and values are normalized to the 
wild type line. (* P <0.05, ** P < 0.01, *** P < 0.001, two-sided Student’s t test).  
 
 
Based on these results, we checked the activation of both ErbB and WNT 
signalling pathways. No evidence for an increase in the phosphorylation of AKT 
and ERK1/2 kinases (Arteaga & Engelman, 2014) was detected in P30 
KSPcdh16/Tcfeb kidneys (Fig. 33) or in primary kidney cells obtained from 
transgenic mice (Fig. 34), indicating that the ErbB pathway was not induced. 
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Figure 33. Activation of ErbB and WNT signalling pathways in kidneys from 
KSPcdh16/Tcfeb mice. 
Immunoblot analyses performed on P30 kidney tissues derived from KSPcdh16/Tcfeb mice to 
evaluate ErbB and WNT activation status. Each replicate is a distinct biological sample. ErbB 
signalling was assessed by looking at phosphoAKT (Ser473) to total AKT ratio, and phosphoERK1 
(T202/Y204)/ERK2(T185/Y187) to total ERK ratio; WNT signalling was assessed by quantifying 
βcatenin and CCND1 (Cyclin D1) protein levels. Graphs represent the densitometry quantification 
of Western blot bands. Values are normalized to tubulin when not specified, and are shown as an 
average (± SEM) (* P <0.05, ** P < 0.01, *** P < 0.001, two-sided, Student’s t test) .  
 
 
RESULTS 
 
113 
 
 
Figure 34. Activation of ErbB and WNT signalling pathways in primary kidney cells. 
Immunoblot analyses performed on primary kidney cells isolated from KSPcdh16/Tcfeb to evaluate 
ErbB and WNT activation status. Each replicate is a distinct biological sample. The same 
antibodies described in figure 33 were used.  Graphs represent the densitometry quantification of 
Western blot bands. Values are normalized to tubulin when not specified, and are shown as an 
average (± SEM) (* P <0.05, ** P < 0.01, *** P < 0.001, two-sided, Student’s t test) .  
 
Erk1/2 activation, as detected by pERK1/2, was observed only at later stages, 
while no pAKT activation was observed (Fig. 35).  
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Figure 35. Biochemical analysis of ErbB signalling in older KSPcdh16/Tcfeb mice. 
Immunoblot analysis performed on P90 kidneys from KSPcdh16/Tcfeb. Each replicate is a different 
biological sample. ErbB was analysed by quantifying phosphoAKT (Ser473) to total AKT, and 
phosphoERK1 (T202/Y204)/ERK2(T185/Y187) to total ERK; graphs are the densitometry 
quantifications of Western blot bands normalized to wild type line and are shown as an average (± 
SEM) (* P <0.05, ** P < 0.01, *** P < 0.001, two-sided Student’s t test).  
 
The same result was found in P90 IndKSPcdh16/Tcfeb mice induced with 
tamoxifen at P14 and at P30 (Fig. 36A, B).  
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Figure 36. Biochemical analysis of ErbB signalling in indKSPcdh16/Tcfeb mice. 
Immunoblot analysis performed on  P90 indKSPcdh16/Tcfeb animals induced with tamoxifen at 
P14 (B) and at P30 (C), respectively. Each replicate is a different biological sample. The same 
antibodies described in figure 33 were used; graphs are the densitometry quantifications of 
Western blot bands normalized to wild type line and are shown as an average (± SEM) (* P <0.05, 
** P < 0.01, *** P < 0.001, two-sided Student’s t test).  
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Conversely, we detected increased levels of total βcatenin and CCND1 in P30 
renal tissues (Fig. 32) and primary kidney cells (Fig. 33) and increased levels of 
non phospho active-βcatenin and of pLRP6 (Ser1490)/ LRP6 ratio in P30 and P90 
renal tissues from KSPcdh16/Tcfeb mice (Fig. 37A, B).  
 
Figure 37. Molecular and analysis of WNT signalling. 
Western blot analysis performed on (A) P30 and (B) P90 kidneys from KSPcdh16/Tcfeb mice to 
assess WNT signalling activation by looking at different proteins related to this pathway. Each 
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replicate is a distinct biological sample. p-LRP6 (Ser1490)/LRP6, active-βcatenin (non phospho), 
βcatenin and p-GSK3β (Ser9)/GSK3β protein levels were quantified by densitometry analysis of 
the Western blot bands. Values are normalized to actin when not specified, and are shown as an 
average (± SEM) (* P <0.05, ** P < 0.01, *** P < 0.001, two-sided Student’s t test).   
 
Moreover, also P90 IndKSPcdh16/Tcfeb mice induced with tamoxifen at P14 and 
at P30 displayed an increased WNT pathway activation (Fig. 38A, B) .  
 
Figure 38. Molecular analysis of WNT signalling pathway in indKSPcdh16/Tcfeb animals. 
A,B) Immunoblot analysis of WNT-related proteins performed on P90 indKSPcdh16/Tcfeb animals 
induced with tamoxifen at P14 (A) and at P30 (B). Each replicate is a different biological sample. 
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Graphs show densitometry analysis of the Western blot bands. Values are normalized to actin 
when not specified, and are shown as an average (± SEM) (* P <0.05, ** P < 0.01, *** P < 0.001, 
two-sided Student’s t test). 
 
 
Finally, immunohistochemistry showed that βcatenin and active-βcatenin staining 
of renal sections from KSPcdh16/Tcfeb mice were significantly enhanced around 
the cysts (Fig. 39). 
 
Figure 39. Histological analysis of WNT signalling. 
Immunohistochemistry staining of CDH16, βcatenin and active-βcatenin proteins performed on P30 
kidney tissues from KSPcdh16/Tcfeb mice. The staining was performed on 4 KSPcdh16/wt and 3 
KSPcdh16/Tcfeb P30 mice. 
 
 
These results indicate the presence of a strong activation of the WNT signalling 
pathway in TFEB-overexpressing mice. Interestingly, the WNT pathway is known 
to play a role in renal cyst development (Vainio & Uusitalo, 2000; Rodova et al, 
2002) and renal tumour formation, such as in Wilm’s tumor (Koesters et al, 1999; 
Zhu et al, 2000; Kim et al, 2000). To investigate the role of TFEB in WNT pathway 
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activation, we performed luciferase assays using a TOP-FLASH Luciferase WNT-
reporter on immortalized kidney cell lines (HEK293 and HK2) co-transfected with 
TFEB and with both βcatenin and TCF4 plasmids to stimulate WNT signalling. 
Luciferase activation was significantly higher in cells transfected with TFEB 
compared to controls without TFEB. No changes were observed when TFEB was 
transfected alone or only with βcatenin (Fig. 40) Together these data suggest that 
TFEB is able to enhance WNT pathway activation.  
 
 
Figure 40. WNT-signalling activation assay. 
Activity of the TCF/LEF reporter TOP-FLASH. Luciferase activity after co-transfection of βcatenin-
TCF plasmids in HEK293 (A) and HK2 (B) cells with and without TFEB overexpression. Values are 
shown as an average (± SEM) of each point in duplicate, normalized to the Renilla values and to 
the basal condition. Data are representative of three independent experiments. 
 
5. Treatment with WNT inhibitors ameliorates the disease 
phenotype 
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Primary kidney cells derived from the renal cortex and medulla of KSPcdh16/Tcfeb 
mice showed significantly higher levels of proliferation compared to wild type cells 
(Fig. 41).  
 
 
Figure 41. Primary kidney cells from KSPcdh16/Tcfeb mice show an hyper-proliferative 
phenotype. 
MTT tetrazolium reduction assay (MTT) was used to evaluate proliferation of primary kidney cells 
derived from KSPcdh16/Tcfeb mice. Values are shown as an average (± SEM) of each point in 
triplicate and normalized versus wild type mice. Data are representative of three independent 
experiments performed on three KSPcdh16/Tcfeb and KSPcdh16/wt mice. 
 
 
We tested whether this hyperproliferative phenotype was sensitive to WNT 
inhibition. Strikingly, cell proliferation was significantly dampened, in a dose-
dependent way, by two small-molecules, PKF118-310 and CGP049090 that 
specifically inhibit the WNT pathway by disrupting the interaction between βcatenin 
and TCF4 (Avila et al, 2006) and are known to suppress cell proliferation in 
several types of cancers, both in vitro and in vivo (Wei et al, 2010; Wakita et al, 
2001) (Fig. 42).  
RESULTS 
 
121 
 
 
Figure 42. Inhibition of WNT signalling rescues the hyper-proliferative phenotype of kidney 
cells from KSPcdh16/Tcfeb mice. 
MTT proliferation assays of primary kidney cells treated independently with two WNT signalling 
inhibitors, PKF118-310 and CGP049090, added at different dosages for 24 hours. 0 µm represents 
the basal proliferation of cells. Values are shown as means (± SEM) of three replicates per point 
normalized to the vehicle (DMSO), added at the same concentration, and versus the KSPcdh16/wt 
cells without drug treatment. Results are representative of three independent experiments 
performed on three KSPcdh16/Tcfeb and KSPcdh16/wt mice. Two-way Anova was applied 
(factors: cell genotype, treatment). 
 
Moreover βcatenin and CCND1 protein levels were highly reduced after PKF118-
310 treatment (Fig. 43). 
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Figure 43. Molecular and analysis of WNT signalling after PKF118-310 treatment. 
Immunoblot analysis on primary kidney cells treated with Drug (PKF118-310) or Vehicle (DMSO) 
for 24 hours at 1.6 µM. Graphs show the densitometry quantifications of Western blot bands. 
Values are normalized to actin and are shown as averages (± SEM) (Cor, cortex; Med, medulla). (* 
P <0.05, ** P < 0.01, *** P < 0.001). 
 
Based on the results obtained in primary kidney cells, we tested whether WNT 
inhibition could ameliorate the disease phenotype in vivo. P21 KSPcdh16/Tcfeb 
transgenic animals were treated with daily IP injections of PKF118-310 for 30 
days. At the end of the treatment they showed an almost complete rescue of the 
observable renal pathology (Fig.44A) and nearly normal KW/BW ratios (Fig. 44B, 
C).  
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Figure 44. Treatment with WNT inhibitor reduces kidney size. 
KSPcdh16/Tcfeb mice treated with Vehicle (DMSO) or Drug (PKF118-310). Pictures (A) and sizes 
(KW/BW) (B) of kidneys from KSPcdh16/Tcfeb mice injected Intraperitoneally (IP) either with 
vehicle or drug at 0.85mg/kg. KW/BW ratios are shown as means (± SEM) and values are 
normalized to the KSPcdh16/wt animals treated with vehicle. C) KW/BW ratio of Vehicle and Drug 
treated mice.  Two-way Anova was applied (factors: treatment, genotype). KW/BW data are relative 
to: 3 Vehicle-treated KSPcdh16/wt mice, 5 Drug-treated KSPcdh16/wt mice, 5 Vehicle-treated 
KSPcdh16/Tcfeb mice and 5 Drug-treated KSPcdh16/Tcfeb mice, 
 
Moreover, we observed a significant reduction of many parameters of cystic and 
neoplastic pathology, such as the number and size of cysts and neoplastic 
papillae, and the levels of Ki67 (Fig. 45A, B, Fig. 46).  
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Figure 45. Treatment with WNT inhibitor attenuates cystic and neoplastic phenotypes. 
A) Ki67 staining of kidneys from KSPcdh16/Tcfeb mice after treatment with vehicle or drug. Insets 
are enlargements of a single cyst. B) Quantification of several parameters related to cysts and 
papillae performed on kidney sections from vehicle- and PKF118-310-treated KSPcdh16/Tcfeb 
mice. Data are relative to 6 Vehicle- and Drug-treated KSPcdh16/Tcfeb mice. This analysis was 
done in collaboration with Prof. Di Fiore in IEO (European Institute of Oncology). The oncologic 
characterization was performed by Dott. Bertalot in IEO. 
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Figure 46. Treatment of KSPcdh16/Tcfeb mice with the WNT inhibitor PKF118-310 partially 
rescues cystic and neoplastic phenotypes. 
Measurements of different parameters related to the cystic and papillary phenotype on 6 animals 
treated with Vehicle (DMSO) and 6 animals treated with Drug (PKF118-310). Values are shown as 
means (± SEM) when appropriate and are represented separately for each animal.  This analysis 
was done in collaboration with Prof. Di Fiore in IEO (European Institute of Oncology). The 
oncologic characterization was performed by Dott. Bertalot in IEO.  
 
We confirmed that drug-treatment in KSPcdh16/Tcfeb mice suppressed the WNT 
pathway both at the mRNA and protein levels, as shown by the reduction of the 
mRNA levels of the WNT direct gene targets Cyclin D1, c-Myc and Axin2 (Fig. 47), 
by the reduction of Cyclin D1 and c-MYC proteins (Fig. 48) and by the decrease of 
Cyclin D1-positive nuclei in KSPcdh16/Tcfeb drug-treated mice (Fig.49). 
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Figure 47. In vivo treatment of KSPcdh16/Tcfeb mice with the PKF118-310 drug inhibits WNT 
target genes 
Tcfeb, Cyclin D1, c-Myc and Axin2 mRNA levels in kidneys from KSPcdh16/wt and 
KSPcdh16/Tcfeb mice treated with vehicle or PKF118-310. Values are shown as the average (± 
SEM) of four animals per group, and are all normalized to the KSPcdh16/wt mice treated with 
vehicle. Two-way Anova was applied (factors: cell genotype, treatment) (* P <0.05, ** P < 
0.01, *** P < 0.001). 
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Figure 48. In vivo treatment of KSPcdh16/Tcfeb mice with the PKF118-310 drug inhibits WNT 
pathway overactivation 
Biochemical analysis performed on  KSPcdh16/wt and KSPcdh16/Tcfeb mice treated with 
vehicle or PKF118-310. Each replicate is a distinct biological sample. Cyclin D1 and c-
MYC  protein levels were quantified by densitometry analysis of Western blot bands. 
Values are normalized to actin when not specified, and are shown as an average (± SEM). 
Two-way Anova was applied (factors: cell genotype, treatment) (* P <0.05, ** P < 0.01, 
*** P < 0.001). 
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Figure 49. In vivo treatment of KSPcdh16/Tcfeb mice with the PKF118-310 drug inhibits 
Cyclin D1 nuclear accumulation 
Cyclin D1 staining performed on Drug- and Vehicle- treated KSPcdh16/Tcfeb mice before and after 
the hematoxylin counterstaining. This IHC staining was performed on six Drug- and Vehicle- 
treated KSPcdh16/Tcfeb mice.  
   
 
 
Furthermore, WNT inhibition resulted in normalization of expression levels of the 
gene encoding the transmembrane Glycoprotein NMB (GPNMB) (Fig. 50A, B), a 
known marker of melanomas, gliomas and breast cancers, which is also 
overexpressed in TFE-fusion ccRCCs  (Malouf et al, 2014; Zhou et al, 2012).  
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Figure 50. Gpnmb gene expression levels. 
Gpnmb mRNA fold activation in kidneys from KSPcdh16/Tcfeb and Tam-treated 
indKSPcdh16/Tcfeb mice at different stages. Values are shown as means (± SEM) of at least three 
mice and each group is normalized to the proper control (respectively KSPcdh16/wt and tam-
treated indKSPcdh16/wt). B) Gpnmb fold activation in kidneys from KSPcdh16/Tcfeb mice treated 
with vehicle or PKF118-310. Values are shown as means (± SEM). We analysed 4  KSPcdh16/wt 
vehicle-treated animals, 5 KSPcdh16/wt drug-treated animals, 4 KSPcdh16/ Tcfeb vehicle-treated 
animals and 4 KSPcdh16/ Tcfeb drug-treated animals., and all the values were normalized versus 
the KSPcdh16/wt mice treated with vehicle. (* P <0.05, ** P < 0.01, *** P < 0.001, two-sided 
Student’s t test).  
 
Interestingly, GPNMB gene resulted to be induced in both the microarray data set, 
as well as in TFE3-tRCC patients, and showed multiple CLEAR elements in its 
promoter (Table 4).  
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Table 4. GPNMB expression table. 
Differentially expression of Gpnmb transcript in KSP_P0 (GSE62977), in KSP_P14 microarray 
dataset (GSE63376) and in RCC dataset. B) Sequence analysis of the CLEAR sites (i.e. the 
consensus TFEB binding sites) in the human and murine promoter region of Gpnmb. 
 
Finally, the overlap of the KSP_P0 microarray dataset with a ChIP-Seq on HeLa 
TFEB-overexpressing cells (Sardiello et al, 2009), revealed that GPNMB was 
shared in both datasets, suggesting to act as a TFEB direct gene target  (Table 5). 
 
Table 5. Microarray and ChIP-Seq overlap. 
List of 11 genes shared between the KSP_P0 dataset and from an HeLA TFEB-overexpressing 
ChIP-Seq dataset. 
 
 
6. Autophagy is not required for disease progression 
Considering the known role of TFEB as a master regulator of the lysosomal-
autophagy pathway (Argani et al, 2001, 2005; Camparo et al, 2008; Davis et al, 
2003), and the recent evidence indicating that activation of autophagy driven by 
MiT/TFE genes plays an important role in pancreatic cancer (Perera et al, 2015), 
we tested whether autophagy plays a role in TFE-tRCC development. We 
analysed the expression levels of a well-characterized panel of TFEB target genes 
known to be involved in lysosomal biogenesis and autophagy in KSPcdh16/Tcfeb 
mice. Surprisingly, no significant changes in the expression levels of these genes 
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were detected in KSPcdh16/Tcfeb compared to wild type mice, with a few 
exceptions (Fig. 51).  
 
 
Figure 51. Expression analysis of lysosomal and autophagy genes in Tcfeb overexpressing 
mice. 
Real-time PCR validation of well-known TFEB direct gene targets whose function is related to the 
lysosomal and autophagic pathways performed on P30 KSPcdh16/Tcfeb mice. Values are shown 
as the average (± SEM) of three KSPcdh16/Tcfeb mice and are normalized to wild type mice (* P 
<0.05, ** P < 0.01, *** P < 0.001, two-sided Student’s t test). 
 
Consistently, immunoblot analysis of the autophagy marker LC3 in kidneys from 
transgenic mice did not reveal any significant changes compared to control 
littermates until P90, where we could detect a reduction of the LC3-II band 
consistent both with an increase or a reduction of the autophagic flux (Fig. 52).  
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Figure 52. Biochemical analysis of LC3I/II protein. 
P14 and P30 kidney lysates from KSPcdh16/Tcfeb animals were evaluated by LC3I/II immunoblot. 
LC3 active / LC3 total ratios were quantified via densitometry of the Western blot bands  (graph). 
Each replicate is a different biological sample. Values are shown as the average (± SEM) of at 
least three KSPcdh16/Tcfeb mice and are normalized to wild type lines. (* P <0.05, ** P < 0.01, *** 
P < 0.001, two-sided, Student’s t test). 
 
Consequently, to test the role of autophagy in the pathogenesis of TFE-tRCC we 
crossed KSPcdh16/Tcfeb mice with autophagy-deficient ATG7flox/flox mice. ATG7-/-
;KSPcdh16 and ATG7-/-;KSPcdh16/Tcfeb animals, as expected, didn’t show ATG7 
protein expression in the kidneys (Fig. 53A), but LC3 staining resulted to be highly 
enhanced in ATG7-/-;KSPcdh16/Tcfeb animals (Fig. 53B), suggesting that TFEB-
overexpressing mice had an increased autophagic flux.  
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Figure 53. ATG7 and LC3 immunohistochemistry in ATG7-/-;KSPcdh16/Tcfeb mice. 
ATG7 (A) and LC3 (B) staining of kidneys from KSPcdh16/Tcfeb and ATG7-/-;KSPcdh16/Tcfeb 
mice. 
 
Despite this, no changes in kidney size or in the cystic phenotype were observed 
in TFEB overexpressing/autophagy-deficient double transgenic mice (ATG7-/-
;KSPcdh16/Tcfeb) compared to KSPcdh16/Tcfeb mice (Fig. 54A, B, C).  
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Figure 54. Inhibition of  autophagy in Tcfeb overexpressing mice does not affect the cystic 
phenotype. 
A) Renal images of (ATG7-/-;KSPcdh16/Tcfeb) double transgenic mice and controls at P30. B) 
Kidney-to-body weight ratio (KW/BW) from the different genotypes obtained. We analysed 5 
ATG7+/+;KSPcdh16/wt  mice, 3 ATG7-/-;KSPcdh16/wt mice, 12 ATG7+/+;KSPcdh16/Tcfeb mice 
and 5 ATG7-/-;KSPcdh16/Tcfeb mice. Values are normalized to the ATG7+/+;KSPcdh16/wt line 
and are shown as an average (± SEM). One-way Anova was applied (factors: genotype) (* P 
<0.05, ** P < 0.01, *** P < 0.001). C) PAS staining of kidneys from the different mouse lines. 
 
These results suggest that autophagy does not play a critical role in the 
development of TFE-tRCC phenotype. 
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Kidney cancers associated with translocations of TFE genes represent a major 
unmet medical need (Argani & Ladanyi, 2005; Komai et al, 2009; Malouf et al, 
2014).  Unfortunately, little is known about the mechanisms underlying this type of 
tumours.  
In most cases TFEB-tRCCs are associated to a well-characterized chromosomal 
translocation involving the TFEB gene and the non-coding Alpha gene, generating 
the alpha-TFEB fusion (t(6;11)(p21.2;q13) (Davis et al, 2003; Kuiper, 2003). Until 
recent reports, TFEB breakpoints were in all cases located upstream exon 3, 
allowing the retention of the entire TFEB coding sequence (Davis et al, 2003; 
Argani et al, 2005; Inamura et al, 2012) and leading to a promoter substitution 
event resulting in a strong up-regulation of the TFEB transcript and protein up to 
60-times (Kuiper, 2003). Only recently a new breakpoint was identified within exon 
4, but the protein size appears to be the same as the wild-type protein (Inamura et 
al, 2012). Rarely, TFEB translocation partners were the KHDBRS2 (inv(6) 
(p21;q11)) (Malouf et al, 2014) and the CLTC (t(6;17)(p21;q23)) genes (Durinck et 
al, 2015). Regarding TFE3-tRCCs, TFE3 gene can translocate with 5 known gene 
partners (i.e. PRCC, ASPSCR1, SFQP, NONO, CLTC), thus generating different 
fusion proteins. The identification of multiple TFE3-gene partners and the 
characterization of some of them (Clark et al, 1997) strongly suggested that RCC 
is caused by TFE3, rather than by its partners (Kauffman et al, 2014). Indeed, 
TFE3 fusion protein resulted to be much more stable and transcriptionally active 
than the wild-type protein (Weterman et al, 2000). Together, these data suggest 
that the first step, and driving force, of the disease pathological cascade is the 
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overexpression of active TFEB and TFE3 proteins, which is likely associated to an 
increase of their transcriptional activity. 
Currently, there are no model systems to study the mechanisms underlying TFE-
tRCC kidney tumours and to identify and test new therapeutic strategies. 
Moreover, there are very limited data available on the biological pathways involved 
in these tumours. The mTOR pathway (Argani et al, 2010) and the MET-tyrosine 
kinase receptor (Tsuda et al, 2007) were found up-regulated in TFE-tRCC 
patients, but targeting of these pathways failed to be effective in therapy (Malouf et 
al, 2010; Wagner et al, 2012; Kauffman et al, 2014). The lack of mechanistic 
insights in TFE-tRCCs has hampered the identification of effective therapeutic 
strategies (Kauffman et al, 2014). Some patients with metastatic TFE3-tRCC have 
been treated with inhibitors of ErbB receptors and of the mTOR pathway. 
Unfortunately, most of these patients relapsed after an initial period of remission 
(Parikh et al, 2009; Wu et al, 2008).   
The lack of knowledge of the mechanisms underlying TFE-tRCCs prompted us to 
generate transgenic mouse models that overexpress TFEB in the kidney, thus 
mimicking the human disease. We generated two transgenic mouse models 
overexpressing TFEB in the epithelial cells of the kidney in either a constitutive 
(KSPcdh16/Tcfeb) or an inducible (IndKSPcdh16/Tcfeb) manner. A severe renal 
cystic pathology associated with a significant increase in renal size was observed 
in these mice. In the constitutive model, cysts arose from the collecting ducts and 
distal tubules, whereas in the inducible one they derived from proximal and distal 
tubules. Our results were in line with previous studies on mouse models of 
polycystic kidney disease, showing that cysts may originate from different cell 
types (Lantinga-van Leeuwen et al. 2007) (Happé et al. 2009) (Leonhard et al. 
2016). These differences were explained considering that different renal segments 
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showed different sensitivity to external stimuli thus leading to different cellular 
responses over time (Lantinga-van Leeuwen et al. 2007) (Happé et al. 2009) 
(Leonhard et al. 2016) (Piontek et al. 2007).  
We observed that cysts were either single- or multi-layered. Epithelial cells lining 
the mono-layered cysts often lost their cuboidal shape, becoming flattened. 
Further analyses revealed the presence of protein casts inside the cysts and multi-
layered basal membranes in the regions surrounding the cysts, due to collagen 
deposition. Interestingly, the presence of fibrosis, mBMs and tubular or cystic 
structures covered by a single layer of flattened, cuboidal, and columnar cells is 
also observed in human patients affected by TFEB-tRCCs (Rao et al, 2012, 2013). 
Finally, in both types of transgenic lines we observed the presence of highly 
enlarged cells with a clear cytoplasm, that closely resemble the “Clear Cells” found 
in human patients with RCC (Rao et al, 2012). 
Transgenic mice also displayed a higher glucose metabolism, as shown by PET-
scan performed in P30 animals suggesting the presence of renal cancer. At P12, 
KSPcdh16/Tcfeb mice already presented cystic changes together with neoplastic 
nodules that were Ki67-positive. The progressive hyper-proliferation of these 
nodules resulted in the development of numerous neoplastic lesions with both 
solid and cystic appearance, ranging from 0.102 to 2.93 mm and sometimes 
showing local invasion of the surrounding stroma. Additionally, liver metastases 
ranging from 0.9 to 3.8 mm, were found in both KSPcdh16/Tcfeb and 
indKSPcdh16/Tcfeb mice. In KSPcdh16/Tcfeb animals they were detected starting 
from P90 with an incidence of 23%. Liver metastases were positive for Ki67, PAX8 
and CDH16, and were negative for cytokeratin 7, consistent with the renal origin of 
the lesions. These data indicate that the newly-generated transgenic lines bear all 
major histological and phenotypic features of human TFE-tRCC (Kauffman et al, 
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2014; Rao et al, 2012, 2013), thus representing excellent models to study this 
disease. 
To identify the effect of TFEB overexpression on the kidney transcriptome we 
performed microarray analysis on kidney samples from P0 KSPcdh16/Tcfeb mice. 
Unexpectedly, transgenic mice did not show a significant induction of the 
autophagy machinery.  We checked by Real-Time PCR the expression levels of 
some of the well-characterized lysosomal and autophagy TFEB gene targets, and 
we could detect the induction of only a few of them. Moreover, crossing of these 
animals with an autophagy deficient ATG7flox/flox mouse line failed to revert the 
disease phenotype. In conclusion, we couldn’t find the presence of a strong 
transcriptional program activating autophagy in the kidney and the specific block of 
this pathway didn’t show effects on the disease phenotype. We believe that the 
overexpression of TFEB in this specific tissue during embryogenesis prompted the 
induction of a different pool of genes. Indeed, transcriptome analysis revealed a 
significant induction of genes involved in the WNT pathway, such as WNT direct 
target genes Ccnd1, c-Myc and Axin2 and WNT-related genes Fzd3, Rnf146 and 
Kdm6a. This transcriptional induction was consistent with increased protein levels 
of total βcatenin, active-βcatenin, CCND1 and pLRP6 (Ser1490)/ LRP6 ratio. 
Furthermore, an induction of the phospho-GSK3β (Ser9)/ GSK3β ratio, an inactive 
form of the GSK3β kinase, was detected at later stages. Hyper-activation of the 
WNT pathway was also observed in cortical and medullary primary kidney cells 
derived from KSPcdh16/Tcfeb mice. Most importantly, luciferase assays 
performed on HEK-293 and HK-2 cells revealed that TFEB overexpression 
resulted in a significant enhancement of WNT pathway activation.  
WNT signalling is of central importance for the development of many organs and 
has been implicated in tumour pathogenesis at different sites. Its activation 
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requires the formation of the WNT signalosome, resulting from the binding of WNT 
ligands to Frizzled (Fzd) receptors. This mediates the interaction of Fzd with 
LRP5/6 proteins. Fzd-LRP5/6 hetero-oligomerization is required to sequester the 
βCatenin degradation complex, containing several kinases such as GSK3 and 
CK1. GSK3 is then able to phosphorylate LRP but not βCatenin. Active-βCatenin, 
which is the non-phosphorylated form of βCatenin, translocates into the nucleus 
and activates its target genes, such as C-MYC, AXIN2 and CCND1 (Clevers, 
2006b), by interacting with the TCF4/LEF1 transcription factors (Voronkov & 
Krauss, 2013).  
Interestingly, hyper-activation of the WNT pathway was recently detected in a 
melanoma cell line in which MITF, another member of the MiT/TFE family, was 
overexpressed, leading to an expansion of the endo-lysosomal compartment that 
in turn was able to concentrate and relocate the WNT signalosome/destruction 
complex and consequently to enhance WNT signalling (Ploper et al, 2015). In 
addition, several studies have linked alterations in the regulation of the βcatenin 
pathway to abnormalities of kidney development and function (Vainio & Uusitalo, 
2000). Indeed, βcatenin is necessary for proper regulation of the PKD1 promoter 
(Rodova et al, 2002), that is mutated in 85% of patients with Autosomal Dominant 
Polycystic Kidney Disease (ADPKD). Unlikely, the role of WNT pathway in cyst 
pathogenesis is still controversial. Mice with overexpression of the Pkd1 transgene 
developed high levels of MYC protein and cystogenesis (Thivierge et al, 2006). 
Conversely, it was recently shown that WNTs can bind the extracellular portion of 
PKD1, thus resulting in whole cell current and Calcium influx, and mutations of 
PKD1 or PKD2 genes suppress the WNT-induced Calcium currents and led to 
cystogenesis (Kim et al. 2016). Furthermore, the WNT pathway is also known to 
play a role in renal tumour formation, such as Wilm’s tumour (Koesters et al, 1999; 
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Zhu et al, 2000; Kim et al, 2000). Mice lacking the Apc gene specifically in the 
kidney are prone to the development of cystic renal cell carcinomas (Sansom et al, 
2005). Finally, cytoplasmic accumulation of βcatenin was observed in patients with 
TFE3-tRCC, suggesting the presence of a possible link between TFE-factors and 
WNT-signaling components (Bruder et al, 2007). Together these studies reveal a 
strong link between hyper-activation of WNT signalling and tumorigenesis in the 
kidney and reinforce our finding of WNT hyper-activation in TFEB transgenic mice 
as a critical step of the disease pathogenesis. 
Based on this evidence, we postulated that treatment with WNT inhibitors had 
beneficial effects on TFE-tRCCs. To test this hypothesis, we treated primary 
kidney cells from KSPcdh16/Tcfeb mice with two small molecules, PKF118-310 
and CGP049090, able to inhibit the WNT pathway by disrupting the interaction 
between βcatenin and TCF-4 (Avila et al, 2006). Drug treatments significantly 
reduced the hyper-proliferation rate observed in cells from transgenic mice, 
bringing it to normal levels. Therefore, we sought to reproduce these data in vivo 
by treating KSPcdh16/Tcfeb mice with WNT inhibitors. Administration of the 
PKF118-310 molecule or vehicle for 30 days resulted in a substantial reduction of 
several important parameters, such as kidney size, cyst number and size, Ki67 
index and the number of neoplastic papillae. Moreover, drug-treated 
KSPcdh16/Tcfeb animals showed a significant decrease in the mRNA levels of 
Gpnmb, a known marker of melanomas, gliomas and breast cancer, which was 
reported to be overexpressed in TFE-fusion ccRCCs (Malouf et al, 2014; Zhou et 
al, 2012). Interestingly, we also found that Gpnmb is a direct transcriptional target 
of TFEB (Sardiello et al, 2009).  
This study provides direct evidence that overexpression of TFEB in the kidney is 
able to generate a severe cystic pathology associated with the development of 
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kidney cancer and liver metastases, thus mimicking the cancer phenotype 
associated with human TFE-fusion ccRCCs chromosomal translocations. Thus, 
the transgenic mouse lines that we generated represent the first genetic animal 
models of renal cell carcinoma. The study of these mice revealed that WNT 
activation plays a crucial role in TFE-tRCCs and that WNT inhibitors can be used 
to rescue the phenotype of our transgenic mouse models, suggesting that 
targeting WNT signalling could be a promising therapeutic approach for the 
treatment of TFE-tRCC patients. 
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